

**Caution:** Forms printed from within Adobe Acrobat may not meet IRS or state taxing agency specifications. When using Acrobat, select the "Actual Size" in the Adobe "Print" dialog.

PUBLIC DISCLOSURE COPY

# TAX RETURN FILING INSTRUCTIONS

\*\* FORM 990 PUBLIC DISCLOSURE COPY \*\*

FOR THE YEAR ENDING  
DECEMBER 31, 2021

<b>Prepared for</b>	PATH 2201 WESTLAKE AVENUE 200 SEATTLE, WA 98121
<b>Prepared by</b>	GELMAN, ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA, MD 20814-2930
<b>Amount due or refund</b>	NOT APPLICABLE
<b>Make check payable to</b>	NOT APPLICABLE
<b>Mail tax return and check (if applicable) to</b>	NOT APPLICABLE
<b>Return must be mailed on or before</b>	NOT APPLICABLE
<b>Special Instructions</b>	THIS RETURN HAS QUALIFIED FOR ELECTRONIC FILING. THE RETURN HAS BEEN TRANSMITTED ELECTRONICALLY TO THE IRS AND NO FURTHER ACTION IS REQUIRED.

Form **990**

**Return of Organization Exempt From Income Tax**  
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

OMB No. 1545-0047

**2021**

Department of the Treasury  
Internal Revenue Service

▶ Do not enter social security numbers on this form as it may be made public.  
▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

Open to Public Inspection

**A For the 2021 calendar year, or tax year beginning and ending**


<b>B</b> Check if applicable: <input type="checkbox"/> Address change <input type="checkbox"/> Name change <input type="checkbox"/> Initial return <input type="checkbox"/> Final return/terminated <input type="checkbox"/> Amended return <input type="checkbox"/> Application pending	<b>C</b> Name of organization PATH		<b>D</b> Employer identification number 91-1157127	
	Doing business as		<b>E</b> Telephone number 206-285-3500	
	Number and street (or P.O. box if mail is not delivered to street address)	Room/suite		
	2201 WESTLAKE AVENUE		200	
City or town, state or province, country, and ZIP or foreign postal code SEATTLE, WA 98121		<b>G</b> Gross receipts \$ 398,901,838.		
<b>F</b> Name and address of principal officer: KELLY PRIESTLEY SAME AS C ABOVE		<b>H(a)</b> Is this a group return for subordinates? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
<b>I</b> Tax-exempt status: <input checked="" type="checkbox"/> 501(c)(3) <input type="checkbox"/> 501(c) ( ) (insert no.) <input type="checkbox"/> 4947(a)(1) or <input type="checkbox"/> 527		<b>H(b)</b> Are all subordinates included? <input type="checkbox"/> Yes <input type="checkbox"/> No		
<b>J</b> Website: WWW.PATH.ORG		If "No," attach a list. See instructions		
<b>K</b> Form of organization: <input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Trust <input type="checkbox"/> Association <input type="checkbox"/> Other		<b>H(c)</b> Group exemption number ▶		
<b>L</b> Year of formation: 1981		<b>M</b> State of legal domicile: WA		

**Part I Summary**

<b>Activities &amp; Governance</b>	<b>1</b> Briefly describe the organization's mission or most significant activities: SEE PART III, LINE 1.		
	<b>2</b> Check this box <input type="checkbox"/> if the organization discontinued its operations or disposed of more than 25% of its net assets.		
	<b>3</b> Number of voting members of the governing body (Part VI, line 1a)	<b>3</b>	16
	<b>4</b> Number of independent voting members of the governing body (Part VI, line 1b)	<b>4</b>	16
	<b>5</b> Total number of individuals employed in calendar year 2021 (Part V, line 2a)	<b>5</b>	667
	<b>6</b> Total number of volunteers (estimate if necessary)	<b>6</b>	0
	<b>7a</b> Total unrelated business revenue from Part VIII, column (C), line 12	<b>7a</b>	0.
<b>b</b> Net unrelated business taxable income from Form 990-T, Part I, line 11	<b>7b</b>	0.	
<b>Revenue</b>	<b>8</b> Contributions and grants (Part VIII, line 1h)	<b>Prior Year</b>	<b>Current Year</b>
	<b>9</b> Program service revenue (Part VIII, line 2g)	287,454,383.	333,068,959.
	<b>10</b> Investment income (Part VIII, column (A), lines 3, 4, and 7d)	0.	0.
	<b>11</b> Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	12,502,251.	9,205,357.
	<b>12</b> Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	1,030,112.	843,270.
<b>Expenses</b>	<b>13</b> Grants and similar amounts paid (Part IX, column (A), lines 1-3)	300,986,746.	343,117,586.
	<b>14</b> Benefits paid to or for members (Part IX, column (A), line 4)	67,994,827.	75,961,955.
	<b>15</b> Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	0.	0.
	<b>16a</b> Professional fundraising fees (Part IX, column (A), line 11e)	132,096,396.	135,407,327.
	<b>b</b> Total fundraising expenses (Part IX, column (D), line 25) ▶ 5,667,202.	0.	0.
	<b>17</b> Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	92,968,260.	123,975,347.
	<b>18</b> Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	293,059,483.	335,344,629.
<b>19</b> Revenue less expenses. Subtract line 18 from line 12	7,927,263.	7,772,957.	
<b>Net Assets or Fund Balances</b>	<b>20</b> Total assets (Part X, line 16)	<b>Beginning of Current Year</b>	<b>End of Year</b>
	<b>21</b> Total liabilities (Part X, line 26)	283,556,203.	307,073,332.
	<b>22</b> Net assets or fund balances. Subtract line 21 from line 20	234,982,056.	253,115,813.
		48,574,147.	53,957,519.

**Part II Signature Block**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

<b>Sign Here</b>	Signature of officer 	Date			
	KELLY PRIESTLEY, CONTROLLER & PRIN. FIN. OFFICER Type or print name and title				
<b>Paid Preparer Use Only</b>	Print/Type preparer's name RICHARD J. LOCASTRO, CPA	Preparer's signature 	Date 11/11/2022	Check if self-employed <input type="checkbox"/>	PTIN P00288314
	Firm's name GELMAN, ROSENBERG & FREEDMAN	Firm's EIN 52-1392008	Phone no. (301) 951-9090		
Firm's address 4550 MONTGOMERY AVE SUITE 800N BETHESDA, MD 20814-2930					

May the IRS discuss this return with the preparer shown above? See instructions  Yes  No

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III [X]

1 Briefly describe the organization's mission: PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? [ ] Yes [X] No If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? [ ] Yes [X] No If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code: ) (Expenses \$ 121,408,713. including grants of \$ 32,739,259. ) (Revenue \$ ) THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, AND MORE. (CONTINUED ON SCHEDULE O)

4b (Code: ) (Expenses \$ 100,080,790. including grants of \$ 33,744,940. ) (Revenue \$ ) ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE. (CONTINUED ON SCHEDULE O)

4c (Code: ) (Expenses \$ 37,745,269. including grants of \$ 4,420,524. ) (Revenue \$ ) AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN SUB-SAHARAN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA: THE DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA - WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR COUNTRY OFFICES INCLUDE: (CONTINUED ON SCHEDULE O)

4d Other program services (Describe on Schedule O.) (Expenses \$ 41,899,328. including grants of \$ 5,057,232. ) (Revenue \$ )

4e Total program service expenses 301,134,100.

Part IV Checklist of Required Schedules

Table with 3 columns: Question Number, Yes, No. Rows include questions 1 through 21 regarding organizational requirements and reporting.

Part IV Checklist of Required Schedules (continued)

Table with 3 columns: Question, Yes, No. Rows 22-38 covering various organizational requirements and reporting obligations.

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V [X]

Table with 3 columns: Question, Yes, No. Rows 1a, 1b, 1c regarding Form 1096, Forms W-2G, and backup withholding rules.

Part V Statements Regarding Other IRS Filings and Tax Compliance (continued)

Table with columns for question number, question text, and Yes/No response boxes. Includes questions 2a through 17 regarding employee counts, tax returns, unrelated business income, foreign accounts, prohibited transactions, and charitable contributions.

Part VI Governance, Management, and Disclosure. For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.

Check if Schedule O contains a response or note to any line in this Part VI [X]

Section A. Governing Body and Management

Table with 3 columns: Question, Yes, No. Rows include: 1a Enter the number of voting members of the governing body at the end of the tax year; 1b Enter the number of voting members included on line 1a, above, who are independent; 2 Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?; 3 Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, trustees, or key employees to a management company or other person?; 4 Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?; 5 Did the organization become aware during the year of a significant diversion of the organization's assets?; 6 Did the organization have members or stockholders?; 7a Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?; 7b Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?; 8 Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following: a The governing body? b Each committee with authority to act on behalf of the governing body?; 9 Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses on Schedule O.

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

Table with 3 columns: Question, Yes, No. Rows include: 10a Did the organization have local chapters, branches, or affiliates?; 10b If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?; 11a Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?; 11b Describe on Schedule O the process, if any, used by the organization to review this Form 990.; 12a Did the organization have a written conflict of interest policy? If "No," go to line 13; 12b Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?; 12c Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe on Schedule O how this was done; 13 Did the organization have a written whistleblower policy?; 14 Did the organization have a written document retention and destruction policy?; 15 Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?; 15a The organization's CEO, Executive Director, or top management official; 15b Other officers or key employees of the organization; 16a Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?; 16b If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?

Section C. Disclosure

- 17 List the states with which a copy of this Form 990 is required to be filed SEE SCHEDULE O
18 Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply. [X] Own website [ ] Another's website [X] Upon request [ ] Other (explain on Schedule O)
19 Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20 State the name, address, and telephone number of the person who possesses the organization's books and records KELLY PRIESTLEY, CONTROLLER & PRINCIPAL FINANCIAL OFFICER - 206-285-3500 2201 WESTLAKE AVE., SUITE 200, SEATTLE, WA 98121

**Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors**

Check if Schedule O contains a response or note to any line in this Part VII

**Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees**

**1a** Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
- List all of the organization's **current** key employees, if any. See the instructions for definition of "key employee."
- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than \$100,000 from the organization and any related organizations.
- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations.
- List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations. See the instructions for the order in which to list the persons above.

Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) NIKOLAJ JESTED GILBERT, MSC PRESIDENT AND CEO	39.00 1.00			X				591,896.	0.	43,730.
(2) DAVID C. KASLOW, MD CHIEF EXECUTIVE-ESSENTIAL MEDICINES	39.00 1.00				X			408,184.	0.	67,963.
(3) TRAD M. HATTON, MA, MHS COUNTRY DIRECTOR	40.00 0.00					X		345,991.	0.	52,997.
(4) ERICA JANE SESSLE, MPHIL, MPH CHIEF OF STAFF (UNTIL 10/1/21)	40.00 0.00				X			355,383.	0.	40,626.
(5) JOHN O. KONZ, PHD GLOBAL HEAD, INT. PTFL. & FIN. MGMT.	40.00 0.00					X		330,414.	0.	64,894.
(6) ASHLEY J. BIRKETT, PHD GLOBAL HEAD, MALARIA VACCINES	40.00 0.00					X		330,205.	0.	59,071.
(7) KIMBERLY GREEN, PHD DIRECTOR, PRIMARY HEALTH CARE	40.00 0.00					X		322,267.	0.	60,231.
(8) JEFFREY D. BERNSON, MPH, MPA CHIEF EXECUTIVE-PROGRAM & INNOVATION	40.00 0.00				X			322,840.	0.	58,884.
(9) BRUCE LAMONT INNIS, MD, FIDSA GLOBAL HEAD, RESPIRATORY INFECTIONS	40.00 0.00					X		342,216.	0.	30,989.
(10) PHILIPPE GUINOT, MBA CHIEF OF BUSINESS, FIN. & OPERATIONS	1.00 39.00			X				0.	316,221.	25,825.
(11) CARLA ANNE COSTA SANDINE CHIEF OF EXTERNAL AFFAIRS	40.00 0.00				X			268,166.	0.	46,608.
(12) MOLLI M. BARNES CHIEF PEOPLE OFFICER	40.00 0.00				X			261,290.	0.	49,413.
(13) SABRINA L. POWERS, JD GENERAL COUNSEL	40.00 0.00				X			265,189.	0.	44,732.
(14) NANTHALILE C. MUGALA, MD, MMED CHIEF EXECUTIVE-AFRICA REGION	40.00 0.00				X			288,679.	0.	0.
(15) DAVID W. FLEMING--SENIOR VP, MD OF PUBLIC HEALTH(UNTIL 2/11/21)	40.00 0.00				X			241,202.	0.	10,041.
(16) ELAINE L. GIBBONS, CFA FRMR VP-GLOBAL ENGMT. (LEFT 2020)	40.00 0.00						X	184,790.	0.	2,056.
(17) JERRY KUO, MBA CHIEF OF STRGC. FIN. (UNTIL 1/4/21)	39.00 1.00			X				134,055.	0.	4,302.

**Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees** (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) BETH GALETTI, MBA CHAIR	2.00 0.00	X		X				0.	0.	0.
(19) DAVID KING, JD VICE CHAIR	2.00 0.00	X		X				0.	0.	0.
(20) SANFORD MELZER SECRETARY	2.00 0.00	X		X				0.	0.	0.
(21) BRUCE MCNAMER, JD, MBA TREASURER	2.00 0.00	X		X				0.	0.	0.
(22) YEHONG ZHANG, PHD, MBA DIRECTOR	2.00 0.00	X						0.	0.	0.
(23) JO ADDY, MBA, MPA DIRECTOR	2.00 0.00	X						0.	0.	0.
(24) IREENA VITTAL DIRECTOR	2.00 0.00	X						0.	0.	0.
(25) DEANNA OPPENHEIMER DIRECTOR	2.00 0.00	X						0.	0.	0.
(26) JOHN-ARNE ROTTINGEN MD, PHD, MSC, MPA--DIRECTOR	2.00 0.00	X						0.	0.	0.
<b>1b Subtotal</b>								4,992,767.	316,221.	662,362.
<b>c Total from continuation sheets to Part VII, Section A</b>								0.	0.	0.
<b>d Total (add lines 1b and 1c)</b>								4,992,767.	316,221.	662,362.

**2** Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization 354

	Yes	No
<b>3</b> Did the organization list any <b>former</b> officer, director, trustee, key employee, or highest compensated employee on line 1a? <i>If "Yes," complete Schedule J for such individual</i>	X	
<b>4</b> For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? <i>If "Yes," complete Schedule J for such individual</i>	X	
<b>5</b> Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? <i>If "Yes," complete Schedule J for such person</i>		X

**Section B. Independent Contractors**

**1** Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RANDSTAD INDIA PVT. LTD., SUITE NO 001 & 002, COPIA, NEW DELHI, INDIA 110025	STAFFING SERVICES	1,796,178.
SAFEGUARD WORLD INT'L, MOSS LANE EDWIN FODEN BUS CENTRE, SANDBACH, UNITED KINGDOM	GENERAL CONTRACTOR	1,322,299.
UNIT4 BUSINESS SOFTWARE, INC. 3 BURLINGTON WOODS, BURLINGTON, MA 01803	SYSTEMS CONTRACTOR	729,988.
PIVOTAL CONSULTING, LLC 1631 15TH AVE W #118, SEATTLE, WA 98119	CONSULTING	600,556.
GLOBALIZATION PARTNERS, INC. 175 FEDERAL ST 17TH FL, BOSTON, MA 02110	STAFFING SERVICES	464,096.

**2** Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 of compensation from the organization 41

SEE PART VII, SECTION A CONTINUATION SHEETS



**Part VIII Statement of Revenue**

Check if Schedule O contains a response or note to any line in this Part VIII

			(A)	(B)	(C)	(D)	
			Total revenue	Related or exempt function revenue	Unrelated business revenue	Revenue excluded from tax under sections 512 - 514	
<b>Contributions, Gifts, Grants and Other Similar Amounts</b>	<b>1 a</b> Federated campaigns	<b>1a</b>					
	<b>b</b> Membership dues	<b>1b</b>					
	<b>c</b> Fundraising events	<b>1c</b>					
	<b>d</b> Related organizations	<b>1d</b>	2,279,943.				
	<b>e</b> Government grants (contributions)	<b>1e</b>	113,800,820.				
	<b>f</b> All other contributions, gifts, grants, and similar amounts not included above	<b>1f</b>	216,988,196.				
	<b>g</b> Noncash contributions included in lines 1a-1f	<b>1g</b>	\$ 3,097,897.				
	<b>h Total.</b> Add lines 1a-1f		333,068,959.				
	<b>Program Service Revenue</b>	<b>2 a</b>	<b>Business Code</b>				
<b>b</b>							
<b>c</b>							
<b>d</b>							
<b>e</b>							
<b>f</b> All other program service revenue							
<b>g Total.</b> Add lines 2a-2f							
<b>Other Revenue</b>	<b>3</b> Investment income (including dividends, interest, and other similar amounts)		8,920,472.			8,920,472.	
	<b>4</b> Income from investment of tax-exempt bond proceeds						
	<b>5</b> Royalties						
	<b>6 a</b> Gross rents	<b>6a</b>	(i) Real				
			(ii) Personal				
	<b>b</b> Less: rental expenses	<b>6b</b>					
	<b>c</b> Rental income or (loss)	<b>6c</b>					
	<b>d</b> Net rental income or (loss)						
	<b>7 a</b> Gross amount from sales of assets other than inventory	<b>7a</b>	(i) Securities	56,047,000.	22,137.		
			(ii) Other				
	<b>b</b> Less: cost or other basis and sales expenses	<b>7b</b>	55,614,599.	169,653.			
	<b>c</b> Gain or (loss)	<b>7c</b>	432,401.	-147,516.			
	<b>d</b> Net gain or (loss)		284,885.			284,885.	
<b>8 a</b> Gross income from fundraising events (not including \$ _____ of contributions reported on line 1c). See Part IV, line 18	<b>8a</b>						
<b>b</b> Less: direct expenses	<b>8b</b>						
<b>c</b> Net income or (loss) from fundraising events							
<b>9 a</b> Gross income from gaming activities. See Part IV, line 19	<b>9a</b>						
<b>b</b> Less: direct expenses	<b>9b</b>						
<b>c</b> Net income or (loss) from gaming activities							
<b>10 a</b> Gross sales of inventory, less returns and allowances	<b>10a</b>						
<b>b</b> Less: cost of goods sold	<b>10b</b>						
<b>c</b> Net income or (loss) from sales of inventory							
<b>Miscellaneous Revenue</b>	<b>11 a</b> OTHER	<b>Business Code</b>	900099	804,482.		804,482.	
	<b>b</b> REIMBURSEMENTS		900099	38,788.		38,788.	
	<b>c</b>						
	<b>d</b> All other revenue						
	<b>e Total.</b> Add lines 11a-11d			843,270.			
<b>12 Total revenue.</b> See instructions			343,117,586.	0.	0.	10,048,627.	

**Part IX Statement of Functional Expenses**

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX

<i>Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.</i>	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
<b>1</b> Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	24,971,209.	24,971,209.		
<b>2</b> Grants and other assistance to domestic individuals. See Part IV, line 22				
<b>3</b> Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	50,990,746.	50,990,746.		
<b>4</b> Benefits paid to or for members				
<b>5</b> Compensation of current officers, directors, trustees, and key employees	3,503,184.	304,810.	3,198,374.	
<b>6</b> Compensation not included above to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)	186,846.		186,846.	
<b>7</b> Other salaries and wages	98,900,832.	84,542,681.	12,401,955.	1,956,196.
<b>8</b> Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	10,846,071.	9,740,836.	866,213.	239,022.
<b>9</b> Other employee benefits	15,530,594.	14,465,840.	968,297.	96,457.
<b>10</b> Payroll taxes	6,439,800.	5,787,905.	592,796.	59,099.
<b>11</b> Fees for services (nonemployees):				
<b>a</b> Management				
<b>b</b> Legal	1,361,906.	689,129.	669,780.	2,997.
<b>c</b> Accounting	941,141.	234,102.	707,039.	
<b>d</b> Lobbying				
<b>e</b> Professional fundraising services. See Part IV, line 17				
<b>f</b> Investment management fees	335,619.		335,619.	
<b>g</b> Other. (If line 11g amount exceeds 10% of line 25, column (A), amount, list line 11g expenses on Sch O.)	21,356,638.	16,798,933.	4,206,724.	350,981.
<b>12</b> Advertising and promotion	259,645.	204,097.	5,771.	49,777.
<b>13</b> Office expenses	8,500,810.	8,062,238.	346,509.	92,063.
<b>14</b> Information technology	7,759,274.	6,314,353.	1,383,166.	61,755.
<b>15</b> Royalties	40,100.	40,100.		
<b>16</b> Occupancy	13,663,995.	254,156.	13,408,822.	1,017.
<b>17</b> Travel	8,854,734.	8,756,823.	97,562.	349.
<b>18</b> Payments of travel or entertainment expenses for any federal, state, or local public officials				
<b>19</b> Conferences, conventions, and meetings	8,927,984.	8,672,961.	254,256.	767.
<b>20</b> Interest	14.	14.		
<b>21</b> Payments to affiliates				
<b>22</b> Depreciation, depletion, and amortization	2,442,094.	9,302.	2,432,792.	
<b>23</b> Insurance	760,860.	460,013.	300,847.	
<b>24</b> Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule O.)				
<b>a</b> SUBCONTRACTORS	32,708,095.	32,708,095.		
<b>b</b> EQUIP RENT & MAINT	11,123,049.	10,973,340.	149,709.	
<b>c</b> DIRECT AID TO BENEF.	986,176.	986,176.		
<b>d</b> FACILITIES ALLOC	0.	13,860,521.	-14,219,377.	358,856.
<b>e</b> All other expenses	3,953,213.	1,305,720.	249,627.	2,397,866.
<b>25</b> Total functional expenses. Add lines 1 through 24e	335,344,629.	301,134,100.	28,543,327.	5,667,202.
<b>26</b> Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.				

Check here  if following SOP 98-2 (ASC 958-720)

**Part X Balance Sheet**

Check if Schedule O contains a response or note to any line in this Part X

		(A) Beginning of year		(B) End of year
<b>Assets</b>	<b>1</b> Cash - non-interest-bearing .....	7,194,550.	<b>1</b>	12,911,863.
	<b>2</b> Savings and temporary cash investments .....	9,719,000.	<b>2</b>	10,006,728.
	<b>3</b> Pledges and grants receivable, net .....	39,742,632.	<b>3</b>	38,296,068.
	<b>4</b> Accounts receivable, net .....	258,036.	<b>4</b>	555,337.
	<b>5</b> Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .....		<b>5</b>	
	<b>6</b> Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) .....		<b>6</b>	
	<b>7</b> Notes and loans receivable, net .....		<b>7</b>	
	<b>8</b> Inventories for sale or use .....		<b>8</b>	
	<b>9</b> Prepaid expenses and deferred charges .....	7,008,112.	<b>9</b>	7,454,031.
	<b>10a</b> Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D .....	<b>10a</b> 37,891,859.		
	<b>b</b> Less: accumulated depreciation .....	<b>10b</b> 30,772,154.	8,413,303.	<b>10c</b> 7,119,705.
	<b>11</b> Investments - publicly traded securities .....	211,220,570.	<b>11</b>	230,729,600.
	<b>12</b> Investments - other securities. See Part IV, line 11 .....		<b>12</b>	
	<b>13</b> Investments - program-related. See Part IV, line 11 .....		<b>13</b>	
	<b>14</b> Intangible assets .....		<b>14</b>	
	<b>15</b> Other assets. See Part IV, line 11 .....		<b>15</b>	
<b>16 Total assets.</b> Add lines 1 through 15 (must equal line 33) .....	283,556,203.	<b>16</b>	307,073,332.	
<b>Liabilities</b>	<b>17</b> Accounts payable and accrued expenses .....	234,982,056.	<b>17</b>	253,115,813.
	<b>18</b> Grants payable .....		<b>18</b>	
	<b>19</b> Deferred revenue .....		<b>19</b>	
	<b>20</b> Tax-exempt bond liabilities .....		<b>20</b>	
	<b>21</b> Escrow or custodial account liability. Complete Part IV of Schedule D .....		<b>21</b>	
	<b>22</b> Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .....		<b>22</b>	
	<b>23</b> Secured mortgages and notes payable to unrelated third parties .....		<b>23</b>	
	<b>24</b> Unsecured notes and loans payable to unrelated third parties .....		<b>24</b>	
	<b>25</b> Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D .....		<b>25</b>	
	<b>26 Total liabilities.</b> Add lines 17 through 25 .....	234,982,056.	<b>26</b>	253,115,813.
<b>Net Assets or Fund Balances</b>	<b>Organizations that follow FASB ASC 958, check here</b> <input checked="" type="checkbox"/> <b>and complete lines 27, 28, 32, and 33.</b>			
	<b>27</b> Net assets without donor restrictions .....	21,554,594.	<b>27</b>	20,653,709.
	<b>28</b> Net assets with donor restrictions .....	27,019,553.	<b>28</b>	33,303,810.
	<b>Organizations that do not follow FASB ASC 958, check here</b> <input type="checkbox"/> <b>and complete lines 29 through 33.</b>			
	<b>29</b> Capital stock or trust principal, or current funds .....		<b>29</b>	
	<b>30</b> Paid-in or capital surplus, or land, building, or equipment fund .....		<b>30</b>	
	<b>31</b> Retained earnings, endowment, accumulated income, or other funds .....		<b>31</b>	
	<b>32</b> Total net assets or fund balances .....	48,574,147.	<b>32</b>	53,957,519.
<b>33</b> Total liabilities and net assets/fund balances .....	283,556,203.	<b>33</b>	307,073,332.	

**Part XI Reconciliation of Net Assets**

Check if Schedule O contains a response or note to any line in this Part XI

<b>1</b>	Total revenue (must equal Part VIII, column (A), line 12)	<b>1</b>	343,117,586.
<b>2</b>	Total expenses (must equal Part IX, column (A), line 25)	<b>2</b>	335,344,629.
<b>3</b>	Revenue less expenses. Subtract line 2 from line 1	<b>3</b>	7,772,957.
<b>4</b>	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	<b>4</b>	48,574,147.
<b>5</b>	Net unrealized gains (losses) on investments	<b>5</b>	-2,389,585.
<b>6</b>	Donated services and use of facilities	<b>6</b>	
<b>7</b>	Investment expenses	<b>7</b>	
<b>8</b>	Prior period adjustments	<b>8</b>	
<b>9</b>	Other changes in net assets or fund balances (explain on Schedule O)	<b>9</b>	0.
<b>10</b>	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))	<b>10</b>	53,957,519.

**Part XII Financial Statements and Reporting**

Check if Schedule O contains a response or note to any line in this Part XII

	Yes	No
<b>1</b> Accounting method used to prepare the Form 990: <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule O.		
<b>2a</b> Were the organization's financial statements compiled or reviewed by an independent accountant? _____ If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis		X
<b>b</b> Were the organization's financial statements audited by an independent accountant? _____ If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: <input type="checkbox"/> Separate basis <input checked="" type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis	X	
<b>c</b> If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? _____ If the organization changed either its oversight process or selection process during the tax year, explain on Schedule O.	X	
<b>3a</b> As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133? _____	X	
<b>b</b> If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why on Schedule O and describe any steps taken to undergo such audits _____	X	

Form **990** (2021)

**SCHEDULE A**  
**(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Public Charity Status and Public Support**

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.  
▶ Attach to Form 990 or Form 990-EZ.

▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

OMB No. 1545-0047

**2021**

Open to Public Inspection

<b>Name of the organization</b>  PATH	<b>Employer identification number</b>  91-1157127
---	---

**Part I Reason for Public Charity Status.** (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

- 1  A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i)**.
- 2  A school described in **section 170(b)(1)(A)(ii)**. (Attach Schedule E (Form 990).)
- 3  A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii)**.
- 4  A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii)**. Enter the hospital's name, city, and state: \_\_\_\_\_
- 5  An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv)**. (Complete Part II.)
- 6  A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v)**.
- 7  An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi)**. (Complete Part II.)
- 8  A community trust described in **section 170(b)(1)(A)(vi)**. (Complete Part II.)
- 9  An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: \_\_\_\_\_
- 10  An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions, subject to certain exceptions; and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2)**. (Complete Part III.)
- 11  An organization organized and operated exclusively to test for public safety. See **section 509(a)(4)**.
- 12  An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2)**. See **section 509(a)(3)**. Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.
  - a  **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
  - b  **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
  - c  **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
  - d  **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
  - e  Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
  - f Enter the number of supported organizations .....
  - g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
<b>Total</b>						

**Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)**

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

**Section A. Public Support**

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
<b>1</b> Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .....	347,844,394.	305,316,107.	286,808,545.	287,454,383.	333,068,959.	1560492388.
<b>2</b> Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .....						
<b>3</b> The value of services or facilities furnished by a governmental unit to the organization without charge ...						
<b>4 Total.</b> Add lines 1 through 3 .....	347,844,394.	305,316,107.	286,808,545.	287,454,383.	333,068,959.	1560492388.
<b>5</b> The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .....						717,318,521.
<b>6 Public support.</b> Subtract line 5 from line 4.						843,173,867.

**Section B. Total Support**

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
<b>7</b> Amounts from line 4 .....	347,844,394.	305,316,107.	286,808,545.	287,454,383.	333,068,959.	1560492388.
<b>8</b> Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources ...	2,050,888.	2,963,587.	6,310,221.	12,207,084.	8,920,472.	32,452,252.
<b>9</b> Net income from unrelated business activities, whether or not the business is regularly carried on ...						
<b>10</b> Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .....	5,225,302.	980,560.	836,870.	1,030,112.	843,270.	8,916,114.
<b>11 Total support.</b> Add lines 7 through 10						1601860754.
<b>12</b> Gross receipts from related activities, etc. (see instructions) .....					12	45,487.
<b>13 First 5 years.</b> If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and <b>stop here</b> .....						<input type="checkbox"/>

**Section C. Computation of Public Support Percentage**

<b>14</b> Public support percentage for 2021 (line 6, column (f), divided by line 11, column (f)).....	<b>14</b>	52.64 %
<b>15</b> Public support percentage from 2020 Schedule A, Part II, line 14 .....	<b>15</b>	53.68 %
<b>16a 33 1/3% support test - 2021.</b> If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and <b>stop here.</b> The organization qualifies as a publicly supported organization .....		<input checked="" type="checkbox"/>
<b>b 33 1/3% support test - 2020.</b> If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and <b>stop here.</b> The organization qualifies as a publicly supported organization .....		<input type="checkbox"/>
<b>17a 10% -facts-and-circumstances test - 2021.</b> If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and <b>stop here.</b> Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization .....		<input type="checkbox"/>
<b>b 10% -facts-and-circumstances test - 2020.</b> If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and <b>stop here.</b> Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization .....		<input type="checkbox"/>
<b>18 Private foundation.</b> If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions .....		<input type="checkbox"/>

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Table with 7 columns: (a) 2017, (b) 2018, (c) 2019, (d) 2020, (e) 2021, (f) Total. Rows include: 1 Gifts, grants, contributions, and membership fees received; 2 Gross receipts from admissions; 3 Gross receipts from activities that are not an unrelated trade or business; 4 Tax revenues levied for the organization's benefit; 5 The value of services or facilities furnished by a governmental unit; 6 Total. Add lines 1 through 5; 7a Amounts included on lines 1, 2, and 3 received from disqualified persons; 7b Amounts included on lines 2 and 3 received from other than disqualified persons; 8 Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Table with 7 columns: (a) 2017, (b) 2018, (c) 2019, (d) 2020, (e) 2021, (f) Total. Rows include: 9 Amounts from line 6; 10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources; 10b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975; 10c Add lines 10a and 10b; 11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on; 12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.); 13 Total support. (Add lines 9, 10c, 11, and 12.)

14 First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here

Section C. Computation of Public Support Percentage

Table with 2 columns: Line number, Percentage. Row 15: Public support percentage for 2021 (line 8, column (f), divided by line 13, column (f)) 15 %; Row 16: Public support percentage from 2020 Schedule A, Part III, line 15 16 %

Section D. Computation of Investment Income Percentage

Table with 2 columns: Line number, Percentage. Row 17: Investment income percentage for 2021 (line 10c, column (f), divided by line 13, column (f)) 17 %; Row 18: Investment income percentage from 2020 Schedule A, Part III, line 17 18 %

19a 33 1/3% support tests - 2021. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization; 19b 33 1/3% support tests - 2020. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization; 20 Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions

**Part IV Supporting Organizations**

(Complete only if you checked a box in line 12 on Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

**Section A. All Supporting Organizations**

	Yes	No
<b>1</b> Are all of the organization's supported organizations listed by name in the organization's governing documents? <i>If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.</i>		
<b>2</b> Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? <i>If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).</i>		
<b>3a</b> Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? <i>If "Yes," answer lines 3b and 3c below.</i>		
<b>b</b> Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? <i>If "Yes," describe in Part VI when and how the organization made the determination.</i>		
<b>c</b> Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? <i>If "Yes," explain in Part VI what controls the organization put in place to ensure such use.</i>		
<b>4a</b> Was any supported organization not organized in the United States ("foreign supported organization")? <i>If "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.</i>		
<b>b</b> Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? <i>If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.</i>		
<b>c</b> Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? <i>If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.</i>		
<b>5a</b> Did the organization add, substitute, or remove any supported organizations during the tax year? <i>If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).</i>		
<b>b Type I or Type II only.</b> Was any added or substituted supported organization part of a class already designated in the organization's organizing document?		
<b>c Substitutions only.</b> Was the substitution the result of an event beyond the organization's control?		
<b>6</b> Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? <i>If "Yes," provide detail in Part VI.</i>		
<b>7</b> Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
<b>8</b> Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? <i>If "Yes," complete Part I of Schedule L (Form 990).</i>		
<b>9a</b> Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? <i>If "Yes," provide detail in Part VI.</i>		
<b>b</b> Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? <i>If "Yes," provide detail in Part VI.</i>		
<b>c</b> Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? <i>If "Yes," provide detail in Part VI.</i>		
<b>10a</b> Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? <i>If "Yes," answer line 10b below.</i>		
<b>b</b> Did the organization have any excess business holdings in the tax year? <i>(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)</i>		

Part IV Supporting Organizations (continued)

Table with 3 columns: Question, Yes, No. Row 11: Has the organization accepted a gift or contribution from any of the following persons? Sub-rows 11a, 11b, 11c.

Section B. Type I Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Did the governing body, members of the governing body, officers acting in their official capacity, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's officers, directors, or trustees at all times during the tax year? Row 2: Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization?

Section C. Type II Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)?

Section D. All Type III Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided? Row 2: Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? Row 3: By reason of the relationship described on line 2, above, did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year?

Section E. Type III Functionally Integrated Supporting Organizations

Table with 3 columns: Question, Yes, No. Row 1: Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions). Sub-rows a, b, c. Row 2: Activities Test. Answer lines 2a and 2b below. Sub-rows a, b. Row 3: Parent of Supported Organizations. Answer lines 3a and 3b below. Sub-rows a, b.

**Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations**

1  Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions.  
All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1	
2	Recoveries of prior-year distributions	2	
3	Other gross income (see instructions)	3	
4	Add lines 1 through 3.	4	
5	Depreciation and depletion	5	
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6	
7	Other expenses (see instructions)	7	
8	<b>Adjusted Net Income</b> (subtract lines 5, 6, and 7 from line 4)	8	

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):		
a	Average monthly value of securities	1a	
b	Average monthly cash balances	1b	
c	Fair market value of other non-exempt-use assets	1c	
d	<b>Total</b> (add lines 1a, 1b, and 1c)	1d	
e	<b>Discount</b> claimed for blockage or other factors (explain in detail in Part VI):		
2	Acquisition indebtedness applicable to non-exempt-use assets	2	
3	Subtract line 2 from line 1d.	3	
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4	
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5	
6	Multiply line 5 by 0.035.	6	
7	Recoveries of prior-year distributions	7	
8	<b>Minimum Asset Amount</b> (add line 7 to line 6)	8	

Section C - Distributable Amount			Current Year
1	Adjusted net income for prior year (from Section A, line 8, column A)	1	
2	Enter 0.85 of line 1.	2	
3	Minimum asset amount for prior year (from Section B, line 8, column A)	3	
4	Enter greater of line 2 or line 3.	4	
5	Income tax imposed in prior year	5	
6	<b>Distributable Amount.</b> Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions).	6	
7	<input type="checkbox"/> Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).		

**Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations** (continued)

<b>Section D - Distributions</b>		<b>Current Year</b>
<b>1</b>	Amounts paid to supported organizations to accomplish exempt purposes	<b>1</b>
<b>2</b>	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	<b>2</b>
<b>3</b>	Administrative expenses paid to accomplish exempt purposes of supported organizations	<b>3</b>
<b>4</b>	Amounts paid to acquire exempt-use assets	<b>4</b>
<b>5</b>	Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	<b>5</b>
<b>6</b>	Other distributions (describe in Part VI). See instructions.	<b>6</b>
<b>7</b>	<b>Total annual distributions.</b> Add lines 1 through 6.	<b>7</b>
<b>8</b>	Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions.	<b>8</b>
<b>9</b>	Distributable amount for 2021 from Section C, line 6	<b>9</b>
<b>10</b>	Line 8 amount divided by line 9 amount	<b>10</b>

<b>Section E - Distribution Allocations</b> (see instructions)	<b>(i) Excess Distributions</b>	<b>(ii) Underdistributions Pre-2021</b>	<b>(iii) Distributable Amount for 2021</b>
<b>1</b> Distributable amount for 2021 from Section C, line 6			
<b>2</b> Underdistributions, if any, for years prior to 2021 (reasonable cause required - explain in Part VI). See instructions.			
<b>3</b> Excess distributions carryover, if any, to 2021			
<b>a</b> From 2016			
<b>b</b> From 2017			
<b>c</b> From 2018			
<b>d</b> From 2019			
<b>e</b> From 2020			
<b>f</b> Total of lines 3a through 3e			
<b>g</b> Applied to underdistributions of prior years			
<b>h</b> Applied to 2021 distributable amount			
<b>i</b> Carryover from 2016 not applied (see instructions)			
<b>j</b> Remainder. Subtract lines 3g, 3h, and 3i from line 3f.			
<b>4</b> Distributions for 2021 from Section D, line 7: \$			
<b>a</b> Applied to underdistributions of prior years			
<b>b</b> Applied to 2021 distributable amount			
<b>c</b> Remainder. Subtract lines 4a and 4b from line 4.			
<b>5</b> Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, explain in Part VI. See instructions.			
<b>6</b> Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. For result greater than zero, explain in Part VI. See instructions.			
<b>7</b> <b>Excess distributions carryover to 2022.</b> Add lines 3j and 4c.			
<b>8</b> Breakdown of line 7:			
<b>a</b> Excess from 2017			
<b>b</b> Excess from 2018			
<b>c</b> Excess from 2019			
<b>d</b> Excess from 2020			
<b>e</b> Excess from 2021			

**Part VI**

**Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions.)

Multiple horizontal lines for supplemental information.

**Schedule B**  
**(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Schedule of Contributors**

▶ **Attach to Form 990 or Form 990-PF.**  
▶ **Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for the latest information.**

OMB No. 1545-0047

**2021**

Name of the organization

PATH

**Employer identification number**

91-1157127

**Organization type**(check one):

**Filers of:**

**Section:**

Form 990 or 990-EZ

501(c)( 3 ) (enter number) organization

4947(a)(1) nonexempt charitable trust **not** treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the **General Rule** or a **Special Rule**.

**Note:** Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

**General Rule**

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling \$5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

**Special Rules**

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of **(1)** \$5,000; or **(2)** 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than \$1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions *exclusively* for religious, charitable, etc., purposes, but no such contributions totaled more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an *exclusively* religious, charitable, etc., purpose. Don't complete any of the parts unless the **General Rule** applies to this organization because it received *nonexclusively* religious, charitable, etc., contributions totaling \$5,000 or more during the year ..... ▶ \$ \_\_\_\_\_

**Caution:** An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it **must** answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

LHA For Paperwork Reduction Act Notice, see the instructions for Form 990, 990-EZ, or 990-PF.

Schedule B (Form 990) (2021)

Name of organization  PATH	Employer identification number  91-1157127
----------------------------------	--

**Part I Contributors** (see instructions). Use duplicate copies of Part I if additional space is needed.

(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
1	<hr/> <hr/> <hr/>	\$ 149,240,935.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
2	<hr/> <hr/> <hr/>	\$ 57,750,252.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
3	<hr/> <hr/> <hr/>	\$ 9,049,765.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
4	<hr/> <hr/> <hr/>	\$ 8,010,343.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
5	<hr/> <hr/> <hr/>	\$ 7,402,978.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)
6	<hr/> <hr/> <hr/>	\$ 6,662,532.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II for noncash contributions.)

Name of organization  PATH	Employer identification number  91-1157127
----------------------------------	--

**Part II Noncash Property** (see instructions). Use duplicate copies of Part II if additional space is needed.

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$ _____	
		\$ _____	
		\$ _____	
		\$ _____	
		\$ _____	
		\$ _____	
		\$ _____	

Name of organization  PATH	Employer identification number  91-1157127
----------------------------------	--

**Part III** Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than \$1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of \$1,000 or less for the year. (Enter this info. once.) ▶ \$ \_\_\_\_\_  
Use duplicate copies of Part III if additional space is needed.

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift	
Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift	
Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift	
Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift	
Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

**SCHEDULE C**  
**(Form 990)**

**Political Campaign and Lobbying Activities**

OMB No. 1545-0047

**2021**

Department of the Treasury  
Internal Revenue Service

For Organizations Exempt From Income Tax Under section 501(c) and section 527  
 ▶ **Complete if the organization is described below. ▶ Attach to Form 990 or Form 990-EZ.**  
 ▶ **Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.**

**Open to Public Inspection**

**If the organization answered "Yes," on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then**

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

**If the organization answered "Yes," on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then**

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

**If the organization answered "Yes," on Form 990, Part IV, line 5 (Proxy Tax) (See separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (See separate instructions), then**

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization  PATH	Employer identification number  91-1157127
----------------------------------	--

**Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.**

- 1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.
- 2 Political campaign activity expenditures ..... ▶ \$ \_\_\_\_\_
- 3 Volunteer hours for political campaign activities ..... \_\_\_\_\_

**Part I-B Complete if the organization is exempt under section 501(c)(3).**

- 1 Enter the amount of any excise tax incurred by the organization under section 4955 ..... ▶ \$ \_\_\_\_\_
- 2 Enter the amount of any excise tax incurred by organization managers under section 4955 ..... ▶ \$ \_\_\_\_\_
- 3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .....  Yes  No
- 4a Was a correction made? .....  Yes  No
- b If "Yes," describe in Part IV.

**Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).**

- 1 Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... ▶ \$ \_\_\_\_\_
- 2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ..... ▶ \$ \_\_\_\_\_
- 3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b ..... ▶ \$ \_\_\_\_\_
- 4 Did the filing organization file **Form 1120-POL** for this year? .....  Yes  No
- 5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ. Schedule C (Form 990) 2021

**Part II-A Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).**

- A** Check  if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
- B** Check  if the filing organization checked box A and "limited control" provisions apply.

<b>Limits on Lobbying Expenditures</b> (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals												
<b>1a</b>	Total lobbying expenditures to influence public opinion (grassroots lobbying)	29,340.													
<b>b</b>	Total lobbying expenditures to influence a legislative body (direct lobbying)	177,826.													
<b>c</b>	Total lobbying expenditures (add lines 1a and 1b)	207,166.													
<b>d</b>	Other exempt purpose expenditures	335,137,463.													
<b>e</b>	Total exempt purpose expenditures (add lines 1c and 1d)	335,344,629.													
<b>f</b>	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000.													
<table border="1" style="width: 100%;"> <thead> <tr> <th style="width: 50%;">If the amount on line 1e, column (a) or (b) is:</th> <th style="width: 50%;">The lobbying nontaxable amount is:</th> </tr> </thead> <tbody> <tr> <td>Not over \$500,000</td> <td>20% of the amount on line 1e.</td> </tr> <tr> <td>Over \$500,000 but not over \$1,000,000</td> <td>\$100,000 plus 15% of the excess over \$500,000.</td> </tr> <tr> <td>Over \$1,000,000 but not over \$1,500,000</td> <td>\$175,000 plus 10% of the excess over \$1,000,000.</td> </tr> <tr> <td>Over \$1,500,000 but not over \$17,000,000</td> <td>\$225,000 plus 5% of the excess over \$1,500,000.</td> </tr> <tr> <td>Over \$17,000,000</td> <td>\$1,000,000.</td> </tr> </tbody> </table>		If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:	Not over \$500,000	20% of the amount on line 1e.	Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000.	Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000.	Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000.	Over \$17,000,000	\$1,000,000.		
If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:														
Not over \$500,000	20% of the amount on line 1e.														
Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000.														
Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000.														
Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000.														
Over \$17,000,000	\$1,000,000.														
<b>g</b>	Grassroots nontaxable amount (enter 25% of line 1f)	250,000.													
<b>h</b>	Subtract line 1g from line 1a. If zero or less, enter -0-	0.													
<b>i</b>	Subtract line 1f from line 1c. If zero or less, enter -0-	0.													
<b>j</b>	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year?		<input type="checkbox"/> Yes <input type="checkbox"/> No												

**4-Year Averaging Period Under Section 501(h)**  
(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)

<b>Lobbying Expenditures During 4-Year Averaging Period</b>						
Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total	
<b>2a</b>	Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
<b>b</b>	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
<b>c</b>	Total lobbying expenditures	224,944.	163,912.	135,193.	207,166.	731,215.
<b>d</b>	Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
<b>e</b>	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
<b>f</b>	Grassroots lobbying expenditures	7,856.		405.	29,340.	37,601.

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

Table with 3 main columns: (a) Yes/No, (b) Amount. Rows include: 1 During the year, did the filing organization attempt to influence foreign, national, state, or local legislation...; 2a Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Table with 3 columns: Question, Yes, No. Rows include: 1 Were substantially all (90% or more) dues received nondeductible by members?; 2 Did the organization make only in-house lobbying expenditures of \$2,000 or less?; 3 Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered "Yes."

Table with 3 columns: Question, Yes, No. Rows include: 1 Dues, assessments and similar amounts from members; 2 Section 162(e) nondeductible lobbying and political expenditures; 3 Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues; 4 If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year?; 5 Taxable amount of lobbying and political expenditures.

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (See instructions); and Part II-B, line 1. Also, complete this part for any additional information.

Blank lines for providing supplemental information as required by the instructions.

SCHEDULE D (Form 990)

Department of the Treasury Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization PATH Employer identification number 91-1157127

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

Table with 3 columns: Question, (a) Donor advised funds, (b) Funds and other accounts. Rows 1-6 covering total number, aggregate value, and donor/grantee information.

Part II Conservation Easements. Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Form for Part II Conservation Easements, including checkboxes for preservation types and a table for lines 2a-2d.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets. Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

Form for Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets, including revenue and asset reporting.

**Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets** (continued)

- 3 Using the organization's acquisition, accession, and other records, check any of the following that make significant use of its collection items (check all that apply):
- a  Public exhibition
  - b  Scholarly research
  - c  Preservation for future generations
  - d  Loan or exchange program
  - e  Other \_\_\_\_\_
- 4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.
- 5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection?  Yes  No

**Part IV Escrow and Custodial Arrangements.** Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

- 1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X?  Yes  No
- b If "Yes," explain the arrangement in Part XIII and complete the following table:
- |                                 | Amount |
|---------------------------------|--------|
| c Beginning balance             | 1c     |
| d Additions during the year     | 1d     |
| e Distributions during the year | 1e     |
| f Ending balance                | 1f     |
- 2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability?  Yes  No
- b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided on Part XIII

**Part V Endowment Funds.** Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	10,930,723.	10,287,113.	9,095,917.	10,056,545.	9,339,249.
b Contributions	2,500.	2,745.	2,100.	1,240.	3,410.
c Net investment earnings, gains, and losses	1,323,367.	1,095,576.	1,691,617.	-494,491.	1,159,282.
d Grants or scholarships					
e Other expenditures for facilities and programs	514,376.	454,711.	502,521.	467,377.	445,396.
f Administrative expenses					
g End of year balance	11,742,214.	10,930,723.	10,287,113.	9,095,917.	10,056,545.

- 2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:
- a Board designated or quasi-endowment  36.0000 %
  - b Permanent endowment  29.0000 %
  - c Term endowment  35.0000 %
- The percentages on lines 2a, 2b, and 2c should equal 100%.
- 3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:
- |  | Yes | No |
|--|-----|----|
| (i) Unrelated organizations  |     | X  |
| (ii) Related organizations   |     | X  |
| b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R? |     |    |
- 4 Describe in Part XIII the intended uses of the organization's endowment funds.

**Part VI Land, Buildings, and Equipment.**

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land				
b Buildings				
c Leasehold improvements		22,543,573.	17,259,728.	5,283,845.
d Equipment		9,534,680.	8,349,319.	1,185,361.
e Other		5,813,606.	5,163,107.	650,499.
<b>Total.</b> Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10c.)				7,119,705.

Part VII Investments - Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

Table with 3 columns: (a) Description of security or category, (b) Book value, (c) Method of valuation. Rows include (1) Financial derivatives, (2) Closely held equity interests, (3) Other (A-H), and Total.

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

Table with 3 columns: (a) Description of investment, (b) Book value, (c) Method of valuation. Rows (1) through (9) and Total.

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

Table with 2 columns: (a) Description, (b) Book value. Rows (1) through (9) and Total.

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

Table with 2 columns: (a) Description of liability, (b) Book value. Row 1 includes (1) Federal income taxes and rows (2) through (9). Total.

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII...

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

Table with 5 main rows and sub-rows (a-e) for adjustments. Columns include line numbers and a shaded area for calculations.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

Table with 5 main rows and sub-rows (a-e) for adjustments. Columns include line numbers and a shaded area for calculations.

Part XIII Supplemental Information.

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:

PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY.

**SCHEDULE F  
(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Statement of Activities Outside the United States**

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.

▶ Attach to Form 990.

▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

OMB No. 1545-0047

**2021**

Open to Public Inspection

Name of the organization  PATH	Employer identification number  91-1157127
--------------------------------------	--

**Part I General Information on Activities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

**1 For grantmakers.** Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? .....  **Yes**  **No**

**2 For grantmakers.** Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

**3 Activities per Region.** (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AFRICA	217,383.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AMEE	165,240.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	BID & PROPOSAL	BID & PROPOSAL	33,612.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	1,261,725.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	FUNDRAISING	FUNDRAISING	109,157.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	1,777,579.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	OTHER	62,676.
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	920,872.
<b>3 a</b> Subtotal .....	0	0			4,548,244.
<b>b</b> Total from continuation sheets to Part I .....	54	1049			206,754,017.
<b>c Totals</b> (add lines 3a and 3b) .....	54	1049			211,302,261.

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule F (Form 990) 2021

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
CENTRAL AMERICA AND THE CARIBBEAN	0	0	GRANTMAKING		929,969.
EAST ASIA AND THE PACIFIC	5	118	PROGRAM SERVICES	AMEE	6,547,799.
EAST ASIA AND THE PACIFIC	0	0	BID & PROPOSAL	BID & PROPOSAL	82,678.
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	7,846,097.
EAST ASIA AND THE PACIFIC	0	0	FUNDRAISING	FUNDRAISING	2,700.
EAST ASIA AND THE PACIFIC	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	1,576,557.
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	OTHER	54,699.
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	2,386,560.
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		9,766,636.
EUROPE	1	5	PROGRAM SERVICES	AFRICA	132,045.
<b>Totals</b> .....					

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
EUROPE	0	0	PROGRAM SERVICES	AMEE	682,847.
EUROPE	0	0	BID & PROPOSAL	BID & PROPOSAL	10,044.
EUROPE	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	17,261,790.
EUROPE	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	2,419,101.
EUROPE	0	0	PROGRAM SERVICES	OTHER	51,211.
EUROPE	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	11,174,147.
EUROPE	0	0	GRANTMAKING		20,410,132.
MIDDLE EAST AND NORTH AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	18,176.
MIDDLE EAST AND NORTH AFRICA	0	0	GRANTMAKING		10,000.
NORTH AMERICA	0	0	PROGRAM SERVICES	AFRICA	9,600.
<b>Totals</b> .....					

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
NORTH AMERICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	616,112.
NORTH AMERICA	0	0	FUNDRAISING	FUNDRAISING	4,995.
NORTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	88,345.
NORTH AMERICA	0	0	PROGRAM SERVICES	OTHER	23,285.
NORTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	699,541.
NORTH AMERICA	0	0	GRANTMAKING		706,919.
RUSSIA AND NEIGHBORING STATES	1	25	PROGRAM SERVICES	AMEE	3,464,908.
RUSSIA AND NEIGHBORING STATES	0	0	BID & PROPOSAL	BID & PROPOSAL	19,196.
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	399.
RUSSIA AND NEIGHBORING STATES	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	653,450.
<b>Totals</b> .....					

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	128,590.
RUSSIA AND NEIGHBORING STATES	0	0	GRANTMAKING		1,829,202.
SOUTH AMERICA	1	5	BID & PROPOSAL	BID & PROPOSAL	610.
SOUTH AMERICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	593,454.
SOUTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	33,701.
SOUTH AMERICA	0	0	PROGRAM SERVICES	OTHER	1,080.
SOUTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	847,838.
SOUTH AMERICA	0	0	GRANTMAKING		1,068,327.
SOUTH ASIA	5	173	PROGRAM SERVICES	AFRICA	14,620.
SOUTH ASIA	0	0	PROGRAM SERVICES	AMEE	14,176,008.
<b>Totals</b> .....					

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
SOUTH ASIA	0	0	BID & PROPOSAL	BID & PROPOSAL	48,403.
SOUTH ASIA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	3,906,531.
SOUTH ASIA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	2,581,026.
SOUTH ASIA	0	0	PROGRAM SERVICES	OTHER	14,339.
SOUTH ASIA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	1,444,393.
SOUTH ASIA	0	0	GRANTMAKING		2,589,327.
SUB-SAHARAN AFRICA	41	723	PROGRAM SERVICES	AFRICA	26,446,647.
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	AMEE	13,792.
SUB-SAHARAN AFRICA	0	0	BID & PROPOSAL	BID & PROPOSAL	196,707.
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	9,523,251.
<b>Totals</b> .....					

**Part I** Continuation of Activities per Region. (Schedule F (Form 990), Part I, line 3)

(a) Region	(b) Number of offices in the region	(c) Number of employees or agents in region	(d) Activities conducted in region (by type) (i.e., fundraising, program services, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region
SUB-SAHARAN AFRICA	0	0	FUNDRAISING	FUNDRAISING	815.
SUB-SAHARAN AFRICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	10,904,369.
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	OTHER	2,666,469.
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	26,394,347.
SUB-SAHARAN AFRICA	0	0	GRANTMAKING		13,680,233.
<b>Totals</b> .....	54	1049			206,754,017.

**Part II** Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		CENTRAL AMERICA AND THE CARIBBEAN	ESSENTIAL MEDICINE	227,985.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	ESSENTIAL MEDICINE	15,000.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	10,524.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	ESSENTIAL MEDICINE	215,408.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	ESSENTIAL MEDICINE	361,052.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	30,000.	CHECK/WIRE	0.		
		CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	70,000.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	71,479.	CHECK/WIRE	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as a tax exempt 501(c)(3) organization by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter ..... ▶ 166

3 Enter total number of other organizations or entities ..... ▶ 50

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	79,069.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	25,000.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	24,100.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	31,654.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	1,059,500.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	71,326.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	57,821.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	166,913.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	24,313.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	AMEE	91,383.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	42,330.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	126,213.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	10,524.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	72,828.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	49,919.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	7,010.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	271,548.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	129,349.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	94,424.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	218,743.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	33,437.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	13,508.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE & PROGRAM INNOVATION	1,721,642.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	66,193.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	243,955.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	17,769.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	3,664,864.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	AMEE	18,921.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	150,000.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	49,988.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	222,394.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	117,367.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	288,175.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	67,463.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	23,575.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	49,441.	CHECK/WIRE	0.		

Part II Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	29,242.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	83,315.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	11,074.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	AMEE	34,649.	CHECK/WIRE	0.		
		EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	130,168.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	464,778.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	38,183.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	224,974.	CHECK/WIRE	0.		
		EUROPE	AFRICA	102,374.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EUROPE	AMEE	212,829.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	1,743,618.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	92,712.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	29,960.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	6,000.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	600,613.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	2,712,511.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	49,500.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	10,296.	CHECK/WIRE	0.		

**Part II** Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE	PROGRAM INNOVATION	1,026,135.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	28,400.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	279,243.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	507,807.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	853,035.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	45,185.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	124,000.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	50,000.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	88,970.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EUROPE	PROGRAM INNOVATION	1,279,135.	CHECK/WIRE	0.		
		EUROPE	AMEE	164,921.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	231,168.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	881,326.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE	225,000.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	1,767,625.	CHECK/WIRE	0.		
		EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	607,577.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	40,000.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	45,000.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		EUROPE	PROGRAM INNOVATION	12,461.	CHECK/WIRE	0.		
		EUROPE	PROGRAM INNOVATION	75,000.	CHECK/WIRE	0.		
		EUROPE	AFRICA, AMEE, ESSENTIAL MEDICINE, & PROGRAM INNOVATION	5,789,794.	CHECK/WIRE	0.		
		MIDDLE EAST & NORTH AFRICA	PROGRAM INNOVATION	10,000.	CHECK/WIRE	0.		
		NORTH AMERICA	ESSENTIAL MEDICINE	124,774.	CHECK/WIRE	0.		
		NORTH AMERICA	PROGRAM INNOVATION	100,000.	CHECK/WIRE	0.		
		NORTH AMERICA	PROGRAM INNOVATION	422,975.	CHECK/WIRE	0.		
		NORTH AMERICA	ESSENTIAL MEDICINE	59,170.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	13,366.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		RUSSIA AND NEIGHBORING STATES	AMEE	85,308.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	45,891.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	45,746.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	17,675.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	82,462.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	29,707.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	25,138.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	14,255.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	176,629.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		RUSSIA AND NEIGHBORING STATES	AMEE	18,457.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	449,620.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	39,901.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	17,227.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	32,985.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	67,892.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	17,698.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	19,542.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	41,708.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		RUSSIA AND NEIGHBORING STATES	PROGRAM INNOVATION	209,012.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	37,400.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	47,434.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	38,192.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	62,796.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	84,569.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	30,998.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	36,033.	CHECK/WIRE	0.		
		RUSSIA AND NEIGHBORING STATES	AMEE	41,560.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SOUTH AMERICA	PROGRAM INNOVATION	168,199.	CHECK/WIRE	0.		
		SOUTH AMERICA	PROGRAM INNOVATION	20,007.	CHECK/WIRE	0.		
		SOUTH AMERICA	ESSENTIAL MEDICINE	362,750.	CHECK/WIRE	0.		
		SOUTH AMERICA	ESSENTIAL MEDICINE	74,798.	CHECK/WIRE	0.		
		SOUTH AMERICA	PROGRAM INNOVATION	15,000.	CHECK/WIRE	0.		
		SOUTH AMERICA	PROGRAM INNOVATION	176,616.	CHECK/WIRE	0.		
		SOUTH AMERICA	ESSENTIAL MEDICINE	56,253.	CHECK/WIRE	0.		
		SOUTH AMERICA	ESSENTIAL MEDICINE	87,883.	CHECK/WIRE	0.		
		SOUTH AMERICA	PROGRAM INNOVATION	106,821.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SOUTH ASIA	AMEE & PROGRAM INNOVATION	46,814.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE & PROGRAM INNOVATION	30,872.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	142,895.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	11,937.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE	35,629.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE	633,973.	CHECK/WIRE	0.		
		SOUTH ASIA	PROGRAM INNOVATION	150,000.	CHECK/WIRE	0.		
		SOUTH ASIA	PROGRAM INNOVATION	268,084.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	10,192.	CHECK/WIRE	0.		

**Part II** Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		SOUTH ASIA	AMEE	69,757.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	8,375.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE	55,000.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	35,613.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE	684,743.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	22,878.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	11,754.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE	7,440.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE & PROGRAM INNOVATION	187,263.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SOUTH ASIA	ESSENTIAL MEDICINE	20,970.	CHECK/WIRE	0.		
		SOUTH ASIA	ESSENTIAL MEDICINE	33,198.	CHECK/WIRE	0.		
		SOUTH ASIA	AMEE & PROGRAM INNOVATION	118,896.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	13,424.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	15,000.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	21,000.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	6,270.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	62,011.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	99,480.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	41,055.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	227,642.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	12,129.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	12,152.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	35,635.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	157,401.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	162,805.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	6,515.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	1,000,000.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	428,863.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	245,842.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	527,263.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	28,851.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	8,509.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	106,638.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	37,800.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	44,460.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	10,846.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	OTHER & PROGRAM INNOVATION	115,300.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	60,018.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	104,684.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	7,683.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	12,611.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	10,682.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	OTHER	8,669.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	537,043.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	539,937.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	399,962.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	246,615.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	247,713.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	491,789.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	58,630.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	475,324.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	26,950.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	124,276.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	OTHER & PROGRAM INNOVATION	38,832.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	167,358.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	456,000.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	OTHER & PROGRAM INNOVATION	24,589.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	14,876.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	115,516.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	5,385.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	12,299.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	1,242,616.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	7,690.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	AFRICA	87,022.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	688,202.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	7,828.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	275,719.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	439,041.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	7,372.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	15,000.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	110,443.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	65,000.	CHECK/WIRE	0.		

<b>Part II</b> Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States. (Schedule F (Form 990), Part II, line 1)								
<b>1</b> <b>(a)</b> Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	<b>(c)</b> Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	<b>(h)</b> Description of non-cash assistance	<b>(i)</b> Method of valuation (book, FMV, appraisal, other)
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	200,000.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA, ESSENTIAL MEDICINE, & PROGRAM INNOVATION	599,874.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	PROGRAM INNOVATION	241,692.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	1,167,548.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	701,521.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	73,356.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	14,584.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	75,234.	CHECK/WIRE	0.		
		SUB-SAHARAN AFRICA	AFRICA	7,831.	CHECK/WIRE	0.		





**Part IV Foreign Forms**

- 1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)* .....  Yes  No
  
- 2 Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)* .....  Yes  No
  
- 3 Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see Instructions for Form 5471)* .....  Yes  No
  
- 4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see Instructions for Form 8621)* .....  Yes  No
  
- 5 Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see Instructions for Form 8865)* .....  Yes  No
  
- 6 Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990)* .....  Yes  No

**Part V Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY

OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND

TECHNICAL MONITORING.

PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND

OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE

GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE

ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH

LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT

ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES

AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT

AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT

FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO

ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.

**SCHEDULE I  
(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Grants and Other Assistance to Organizations,  
Governments, and Individuals in the United States**  
Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.  
▶ **Attach to Form 990.**  
▶ **Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for the latest information.**

OMB No. 1545-0047

**2021**

**Open to Public  
Inspection**

Name of the organization PATH Employer identification number 91-1157127

**Part I General Information on Grants and Assistance**

- 1** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance?  **Yes**  **No**
- 2** Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

**Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments.** Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed.

<b>1 (a)</b> Name and address of organization or government	<b>(b)</b> EIN	<b>(c)</b> IRC section (if applicable)	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	<b>(g)</b> Description of noncash assistance	<b>(h)</b> Purpose of grant or assistance
ABT ASSOCIATES INC. 6130 EXECUTIVE BLVD ROCKVILLE, MD 20852	04-2347643	OTHER	9,708.	0.			PROGRAM INNOVATION
ADARA DEVELOPMENT (USA) 300 ADMIRAL WY, SUITE 106 EDMONDS, WA 98020	98-0634789	501(C)(3)	93,108.	0.			PROGRAM INNOVATION
AJINOMOTO ALTHEA, INC. (DBA AJINOMOTO BIO-PHARMA SERVICES) - 11040 ROSELLE STREET - SAN DIEGO, CA 92121	33-0788907	OTHER	11,430.	0.			ESSENTIAL MEDICINES
AKROS, INC. PO BOX 457 LARAMIE, WY 82073		OTHER	75,197.	0.			PROGRAM INNOVATION
BAGAMIAN SCIENTIFIC CONSULTING 222 NW 3RD AVE GAINESVILLE, FL 32601	82-1347380	501(C)(3)	149,150.	0.			ESSENTIAL MEDICINES
BENEVOLENT HEALTHCARE FOUNDATION D.B.A. PROJECT C.U.R.E - 10377 E. GEDDES AVENUE, SUITE 200 - CENTENNIAL, CO 80112	84-1568566	501(C)(3)	25,153.	0.			AFRICA

**2** Enter total number of section 501(c)(3) and government organizations listed in the line 1 table 58.

**3** Enter total number of other organizations listed in the line 1 table 20.

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule I (Form 990) 2021

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
CENTERS FOR DISEASE CONTROL AND PREVENTION - 1600 CLIFTON ROAD - ATLANTA, GA 30333	58-6051157	GOV	71,634.	0.			ESSENTIAL MEDICINES
CHILDREN'S HOSPITAL BOSTON RESEARCH FINANCE, PO BOX 414413 BOSTON, MA 02241-4413	04-2774441	501(C)(3)	377,756.	0.			ESSENTIAL MEDICINES
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, 3333 BURNET AVE, ML 6014 - CINCINNATI, OH 45229-3039	31-0833936	501(C)(3)	230,000.	0.			ESSENTIAL MEDICINES
CLINTON HEALTH ACCESS INITIATIVE 383 DORCHESTER AVE., SUITE 400 BOSTON, MA 02127	27-1414646	501(C)(3)	1,821,638.	0.			PROGRAM INNOVATION
COOPER/SMITH 4206 RIVER RD NW WASHINGTON, DC 20016	47-2387850	OTHER	188,947.	0.			PROGRAM INNOVATION
DARTMOUTH-HITCHCOCK CLINIC ONE MEDICAL CENTER DR LEBANON, NH 03756	22-2715483	501(C)(3)	199,968.	0.			ESSENTIAL MEDICINES
DIMAGI, INC. 585 MASSACHUSETTS AVE. SUITE 4 CAMBRIDGE, MA 02139	83-0343298	501(C)(3)	287,935.	0.			PROGRAM INNOVATION
FOOD AND DRUG ADMINISTRATION 5600 FISHERS LN, HFA-140, RM 11-40 ROCKVILLE, MD 20857	53-0196965	GOV	75,000.	0.			ESSENTIAL MEDICINES
G&L SCIENTIFIC INC 25 INDEPENDENCE BLVD SUITE 404 WARREN, NJ 07059	81-1114075	OTHER	12,360.	0.			PROGRAM INNOVATION

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
GLOBAL CONNECT DEVELOPMENT GROUP LLC - 480 BEACH ST - BOSTON, MA 02131	82-3433604	OTHER	398,175.	0.			PROGRAM INNOVATION
GLOBAL HEALTH STRATEGIES LLC 27 WEST 24TH STREET, SUITE 900 NEW YORK, NY 10010	27-2494697	501(C)(3)	264,021.	0.			PROGRAM INNOVATION
GUARALDI SYSTEMS, LLC 97 ALGER BROOK RD SOUTH STAFFORD, VT 05070	85-1148274	OTHER	276,640.	0.			PROGRAM INNOVATION
HARVARD SCHOOL OF PUBLIC HEALTH 677 HUNTINGTON AVENUE BOSTON, MA 02215	04-2103580	501(C)(3)	1,415,739.	0.			ESSENTIAL MEDICINES
HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE. 2ND FLOOR CAMBRIDGE, MA 02115	04-2103580	501(C)(3)	157,819.	0.			ESSENTIAL MEDICINES & PROGRAM INNOVATION
HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC. - 6720-A ROCKLEDGE DRIVE, STE. 100 - BETHESDA, MD	52-1317896	501(C)(3)	10,663.	0.			ESSENTIAL MEDICINES
HISP US LLC 31 ANCONA AVE OCEAN PARK, ME 04063	85-0894858	OTHER	310,352.	0.			PROGRAM INNOVATION
HJF MEDICAL RESEARCH INTERNATIONAL INC. - 6720A ROCKLEDGE DRIVE, SUITE 100 - BETHESDA, MD 20817	52-2322791	501(C)(3)	63,260.	0.			ESSENTIAL MEDICINES
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - 1 GUSTAVE L. LEVY PLACE - NEW YORK, NY 10029	13-6171197	501(C)(3)	535,000.	0.			ESSENTIAL MEDICINES

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
ICF MACRO, INC. 9300 LEE HIGHWAY FAIRFAX, VA 22031	22-3661438	OTHER	2,049,999.	0.			PROGRAM INNOVATION
INDIANA UNIVERSITY 107 S INDIAN AVE BLOOMINGTON, IN 47405	35-6001673	GOV	148,623.	0.			PROGRAM INNOVATION
INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI) - 1201 EYE STREET NW - WASHINGTON, DC 20005	52-1041632	501(C)(3)	16,666.	0.			PROGRAM INNOVATION
INTRAHEALTH INTERNATIONAL, INC 6340 QUADRANGLE DRIVE, SUITE 200 CHAPEL HILL, NC 27517	55-0825466	501(C)(3)	824,333.	0.			AFRICA & PROGRAM INNOVATION
IPAS 300 MARKET ST #200 CHAPEL HILL, NC 27516	56-1071085	501(C)(3)	63,941.	0.			PROGRAM INNOVATION
JHPIEGO 1615 THAMES STREET, SUITE 200 BALTIMORE, MD 21231-3447	23-7424444	501(C)(3)	437,778.	0.			AFRICA & AMEE
JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHL OF PUB. HLTH, 615 N. WOLFE STREET - BALTIMORE, MD 21205	52-0595110	501(C)(3)	10,566.	0.			ESSENTIAL MEDICINES
JSI RESEARCH AND TRAINING INSTITUTE, INC. - 1616 NORTH FORT MYER DR 16TH FLOOR - ARLINGTON, VA 22209-3100	04-2679824	501(C)(3)	1,138,899.	0.			PROGRAM INNOVATION
KINDEVA DRUG DELIVERY L.P. 11200 HUDSON RD WOODBURY, MN 55129		OTHER	146,960.	0.			PROGRAM INNOVATION

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
LEIDOS BIOMEDICAL RESEARCH INC. 1050 BOYLES ST FREDERICK, MD 21702	33-0653185	OTHER	148,511.	0.			ESSENTIAL MEDICINES
LINKSBRIDGE SPC 101 TAYLOR AVE N. #105 SEATTLE, WA 98109	26-3067893	OTHER	27,849.	0.			ESSENTIAL MEDICINES
MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION (MWRI) - 3339 WARD ST - PITTSBURGH, PA 15213	25-1462312	501(C)(3)	35,761.	0.			PROGRAM INNOVATION
MANAGEMENT SCIENCES FOR HEALTH, INC. - 200 RIVERS EDGE DRIVE, SUITE 320 - MEDFORD, MA 02155	04-2482188	501(C)(3)	111,280.	0.			PROGRAM INNOVATION
MASSACHUSETTS GENERAL HOSPITAL DEPT. OF EMERGENCY MEDICINE, ZERO BOSTON, MA 02114	04-1564655	501(C)(3)	22,298.	0.			ESSENTIAL MEDICINES
MEDIC MOBILE, INC. 3254 19TH STREET FLOOR 2 SAN FRANCISCO, CA 94110	27-5104203	501(C)(3)	100,439.	0.			PROGRAM INNOVATION
MICHIGAN STATE UNIVERSITY 3900 COLLINS RD SUITE 1044 LANSING, MI 48910	38-6005984	501(C)(3)	148,595.	0.			PROGRAM INNOVATION
NATIONAL FOUNDATION FOR THE CDC 55 PARK PLACE SUITE 400 ATLANTA, GA 30303	58-2106707	501(C)(3)	51,394.	0.			ESSENTIAL MEDICINES
NAT'L INST. OF ALLERGY & INFECTIOUS DISEASES (NIAID) - 6610 ROCKLEDGE DR, ROOM 2800 - BETHESDA, MD 20892-6606	52-0858115	GOV	260,000.	0.			ESSENTIAL MEDICINES

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
NICHOLAS INST. FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY - 2117 CAMPUS DR P.O. BOX 90335 - DURHAM, NC 27708	56-0532129	501(C)(3)	15,333.	0.			PROGRAM INNOVATION
ONA SYSTEMS INC 126 E 12TH ST, SUITE 4A NEW YORK, NY 10003-5320	38-3940780	OTHER	256,923.	0.			PROGRAM INNOVATION
OPEN FUNCTION GROUP LLC 66 EUCLID AVE HASTINGS ON HUDSON, NY 10706		OTHER	62,200.	0.			PROGRAM INNOVATION
OPENMRS INC. 10425 COMMERCE DR, STE 110 CARMEL, IN 46032-7643	45-5316647	501(C)(3)	129,443.	0.			PROGRAM INNOVATION
PARTNERS IN HEALTH A NONPROFIT CORPORATION - 800 BOYLSTON ST SUITE 300 - BOSTON, MA 02199	04-3567502	501(C)(3)	24,608.	0.			PROGRAM INNOVATION
PATHFINDER INTERNATIONAL 9 GALEN STREET, SUITE 217 WATERTOWN, MA 02472	53-0235320	501(C)(3)	104,629.	0.			PROGRAM INNOVATION
PHARMARON CPC, INC. 800 W. BALTIMORE STREET, 5TH FLOOR BALTIMORE, MD 21201	20-8419781	OTHER	76,832.	0.			ESSENTIAL MEDICINES
POPULATION COUNCIL ONE DAG HAMMERKJOLD PLAZA NEW YORK, NY 10017	13-1687001	501(C)(3)	113,568.	0.			PROGRAM INNOVATION
POPULATION SERVICES INTERNATIONAL INC. - 1120 19TH ST NW, STE 600 - WASHINGTON, DC 20036	56-0942853	501(C)(3)	640,025.	0.			AMEE & PROGRAM INNOVATION

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
REGENSTRIEF INSTITUTE, INC. 1101 W 10TH ST INDIANAPOLIS, IN 46202	30-0007730	501(C)(3)	1,245,318.	0.			PROGRAM INNOVATION
ROSTROPOVICH-VISHNEVSKAYA FOUNDATION - 1776 K STREET NW, SUITE 700 - WASHINGTON, DC 20006	52-1752473	501(C)(3)	69,530.	0.			ESSENTIAL MEDICINES
RTI INTERNATIONAL P.O. BOX 12106 DURHAM, NC 27709-2106	56-0686338	501(C)(3)	167,169.	0.			PROGRAM INNOVATION
SOLAR ELECTRIC LIGHT FUND 1612 K STREET, NW, SUITE 300 WASHINGTON, DC 20006	52-1701564	501(C)(3)	32,052.	0.			PROGRAM INNOVATION
SYSTEMONE, LLC 5 BRIDGE STREET SHELBURNE FALLS, MA 01370	46-1066795	OTHER	178,199.	0.			AMEE
TECHCHANGE, INC. 2001 13TH ST. NW 2ND FLOOR WASHINGTON, DC 20009	27-3358772	OTHER	401,650.	0.			PROGRAM INNOVATION
TECHNICAL RESOURCES INTERNATIONAL, INC. (TRI) - 6500 ROCK SPRING DR SUITE 650 - BETHESDA, MD 20817	52-1122901	OTHER	14,582.	0.			ESSENTIAL MEDICINES
THE NATURE CONSERVANCY 4245 FAIRFAX DRIVE ARLINGTON, VA 22203	53-0242652	501(C)(3)	28,818.	0.			PROGRAM INNOVATION
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA (UVA) - 1001 N EMMET ST - CHARLOTTESVILLE, VA 22903	54-6001796	501(C)(3)	66,037.	0.			ESSENTIAL MEDICINES

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
THE REGENTS OF THE UNIVERSITY OF CA, SF - UCSF OFFICE OF SPONSORED RES., 3333 CALIFORNIA ST, STE 315 - SAN FRANCISCO, CA 94118	94-6036493	501(C)(3)	199,937.	0.			PROGRAM INNOVATION
THE STATE UNIVERSITY OF NEW YORK 35 STATE STREET ALBANY, NY 12207-2826	14-1368361	501(C)(3)	41,040.	0.			ESSENTIAL MEDICINES
TULANE UNIVERSITY 6823 ST. CHARLES AVE NEW ORLEANS, LA 70112	72-0423889	501(C)(3)	535,028.	0.			ESSENTIAL MEDICINES & PROGRAM INNOVATION
UNITED NATIONS FOUNDATION, INC. 1750 PENNSYLVANIA AVE, NW STE 300 WASHINGTON, DC 20006	58-2368165	501(C)(3)	178,680.	0.			PROGRAM INNOVATION
UNIVERSITY OF CALIFORNIA LOS ANGELES (UCLA) - 10889 WILSHIRE BLVD SUITE 700 - LOS ANGELES, CA 90095	95-6006143	GOV	276,086.	0.			AFRICA
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. - 310 E CAMPUS RD - ATHENS, GA 30602	58-1353149	501(C)(3)	71,437.	0.			ESSENTIAL MEDICINES
UNIVERSITY OF MARYLAND BALTIMORE BALTIMORE, PO BOX 41428 BALTIMORE, MD 21203-6428	52-6002033	GOV	91,228.	0.			ESSENTIAL MEDICINES
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL, 55 LAKE AVE NORTH WORCESTER, MA 01655	04-3167352	GOV	198,235.	0.			PROGRAM INNOVATION
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL - CENTER FOR INFECTIOUS DISEASES - CHAPEL HILL, NC 27599-3368	56-6001393	501(C)(3)	618,814.	0.			ESSENTIAL MEDICINES & PROGRAM INNOVATION

Schedule I (Form 990)

**Part II** Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE - 85 SOUTH PROSPECT STREET - BURLINGTON, VT 05405	03-0179440	501(C)(3)	313,359.	0.			ESSENTIAL MEDICINES
UNIVERSITY OF WASHINGTON (UW) GRANT & CONTRACT ACCOUNTING, 12455 COLLECTIONS DRIVE - CHICAGO, IL 60693	91-6001537	501(C)(3)	1,500,176.	0.			ESSENTIAL MEDICINES & PROGRAM INNOVATION
VILLAGEREACH 2900 EASTLAKE AVE E, SUITE 230 SEATTLE, WA 98102-3012	91-2088484	501(C)(3)	283,330.	0.			AFRICA & PROGRAM INNOVATION
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY - 300 TURNER ST NW SUITE 4200 - BLACKSBURG, VA 24061	54-6001805	GOV	76,922.	0.			ESSENTIAL MEDICINES
VITAL STRATEGIES, INC 100 BROADWAY, 4TH FLOOR NEW YORK, NY 10005	22-3419667	501(C)(3)	218,104.	0.			PROGRAM INNOVATION
VITAL WAVE, INC. 555 BRYANT STREET, #226 PALO ALTO, CA 94301	20-3208079	OTHER	813,825.	0.			PROGRAM INNOVATION
WALTER REED ARMY INSTITUTE OF RESEARCH - US TREASURY, 503 ROBERT GRANT AVE. - SILVER SPRING, MD 20910	52-0664528	GOV	2,812,443.	0.			ESSENTIAL MEDICINES
WASHINGTON STATE UNIVERSITY 901 5TH AVE SUITE 2900 SEATTLE, WA 98164	91-6001108	GOV	310,104.	0.			AFRICA

**Part III Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22.  
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

**Part IV Supplemental Information.** Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

PART I, LINE 2:

PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR

PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND

TECHNICAL MONITORING.

PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND

OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE

GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE

ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS,



**SCHEDULE J  
(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Compensation Information**

For certain Officers, Directors, Trustees, Key Employees, and Highest  
Compensated Employees

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 23.

▶ Attach to Form 990.

▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

OMB No. 1545-0047

**2021**

Open to Public  
Inspection

Name of the organization

PATH

Employer identification number

91-1157127

**Part I Questions Regarding Compensation**

**1a** Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

- |   |   |
|---|---|
| <input type="checkbox"/> First-class or charter travel                        | <input checked="" type="checkbox"/> Housing allowance or residence for personal use |
| <input type="checkbox"/> Travel for companions                                | <input type="checkbox"/> Payments for business use of personal residence            |
| <input checked="" type="checkbox"/> Tax indemnification and gross-up payments | <input type="checkbox"/> Health or social club dues or initiation fees              |
| <input type="checkbox"/> Discretionary spending account                       | <input type="checkbox"/> Personal services (such as maid, chauffeur, chef)          |

**b** If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

**2** Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a? .....

**3** Indicate which, if any, of the following the organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> Compensation committee              | <input type="checkbox"/> Written employment contract                                |
| <input checked="" type="checkbox"/> Independent compensation consultant | <input checked="" type="checkbox"/> Compensation survey or study                    |
| <input type="checkbox"/> Form 990 of other organizations                | <input checked="" type="checkbox"/> Approval by the board or compensation committee |

**4** During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

- a** Receive a severance payment or change-of-control payment? .....
- b** Participate in or receive payment from a supplemental nonqualified retirement plan? .....
- c** Participate in or receive payment from an equity-based compensation arrangement? .....
- If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

**Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.**

**5** For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:

- a** The organization? .....
- b** Any related organization? .....
- If "Yes" on line 5a or 5b, describe in Part III.

**6** For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:

- a** The organization? .....
- b** Any related organization? .....
- If "Yes" on line 6a or 6b, describe in Part III.

**7** For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III .....

**8** Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III .....

**9** If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .....

	Yes	No
<b>1b</b>	X	
<b>2</b>	X	
<b>4a</b>	X	
<b>4b</b>		X
<b>4c</b>		X
<b>5a</b>		X
<b>5b</b>		X
<b>6a</b>		X
<b>6b</b>		X
<b>7</b>	X	
<b>8</b>		X
<b>9</b>		

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule J (Form 990) 2021

**Part II Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

**Note:** The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC and/or 1099-NEC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
(1) NIKOLAJ JESTED GILBERT, MSC PRESIDENT AND CEO	(i)	455,096.	135,000.	1,800.	34,200.	9,530.	635,626.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) DAVID C. KASLOW, MD CHIEF EXECUTIVE-ESSENTIAL MEDICINES	(i)	406,234.	0.	1,950.	34,200.	33,763.	476,147.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) TRAD M. HATTON, MA, MHS COUNTRY DIRECTOR	(i)	145,889.	0.	200,102.	17,613.	35,384.	398,988.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) ERICA JANE SESSLE, MPHIL, MPH CHIEF OF STAFF (UNTIL 10/1/21)	(i)	166,386.	0.	188,997.	21,156.	19,470.	396,009.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) JOHN O. KONZ, PHD GLOBAL HEAD, INT. PTFL. & FIN. MGMT.	(i)	329,574.	0.	840.	32,831.	32,063.	395,308.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) ASHLEY J. BIRKETT, PHD GLOBAL HEAD, MALARIA VACCINES	(i)	329,140.	0.	1,065.	29,551.	29,520.	389,276.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(7) KIMBERLY GREEN, PHD DIRECTOR, PRIMARY HEALTH CARE	(i)	270,667.	0.	51,600.	24,087.	36,144.	382,498.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(8) JEFFREY D. BERNSON, MPH, MPA CHIEF EXECUTIVE-PROGRAM & INNOVATION	(i)	322,840.	0.	0.	32,628.	26,256.	381,724.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(9) BRUCE LAMONT INNIS, MD, FIDSA GLOBAL HEAD, RESPIRATORY INFECTIONS	(i)	341,376.	0.	840.	32,831.	-1,842.	373,205.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(10) PHILIPPE GUINOT, MBA CHIEF OF BUSINESS, FIN. & OPERATIONS	(i)	0.	0.	0.	0.	0.	0.	0.
	(ii)	309,985.	0.	6,236.	24,840.	985.	342,046.	0.
(11) CARLA ANNE COSTA SANDINE CHIEF OF EXTERNAL AFFAIRS	(i)	267,566.	0.	600.	29,684.	16,924.	314,774.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(12) MOLLI M. BARNES CHIEF PEOPLE OFFICER	(i)	261,290.	0.	0.	26,317.	23,096.	310,703.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(13) SABRINA L. POWERS, JD GENERAL COUNSEL	(i)	263,164.	0.	2,025.	31,728.	13,004.	309,921.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(14) NANTHALILE C. MUGALA, MD, MMED CHIEF EXECUTIVE-AFRICA REGION	(i)	208,499.	0.	80,180.	0.	0.	288,679.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(15) DAVID W. FLEMING--SENIOR VP, MD OF PUBLIC HEALTH(UNTIL 2/11/21)	(i)	42,434.	0.	198,768.	8,176.	1,865.	251,243.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.
(16) ELAINE L. GIBBONS, CFA FRMR VP-GLOBAL ENGMT. (LEFT 2020)	(i)	0.	0.	184,790.	2,056.	0.	186,846.	0.
	(ii)	0.	0.	0.	0.	0.	0.	0.

**Part III Supplemental Information**

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 1A:

HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE

INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE

ACCORDING TO OUR EXPATRIATE POLICY.

PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE

COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN

ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET

MOVEMENT.

PART I, LINE 4A:

LIST OF PERSONS IN FORM 990, PART VII, SECTION A WHO RECEIVED SEVERANCE

PAYMENTS IN 2021:

- DAVID W. FLEMING \$172,266

- ELAINE L. GIBBONS \$143,508

- JERRY KUO \$99,570

- ERICA JANE SESSLE \$170,055

**Part III Supplemental Information**

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 7:

BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II).

**SCHEDULE M  
(Form 990)**

**Noncash Contributions**

OMB No. 1545-0047

**2021**

Department of the Treasury  
Internal Revenue Service

- ▶ Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
- ▶ Attach to Form 990.
- ▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

Open to Public Inspection

Name of the organization  PATH	Employer identification number  91-1157127
--------------------------------------	--

Part I Types of Property	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art - Works of art .....				
2 Art - Historical treasures .....				
3 Art - Fractional interests .....				
4 Books and publications .....				
5 Clothing and household goods .....				
6 Cars and other vehicles .....				
7 Boats and planes .....				
8 Intellectual property .....				
9 Securities - Publicly traded .....	X	14	9,567.	FMV
10 Securities - Closely held stock .....				
11 Securities - Partnership, LLC, or trust interests .....				
12 Securities - Miscellaneous .....				
13 Qualified conservation contribution - Historic structures .....				
14 Qualified conservation contribution - Other .....				
15 Real estate - Residential .....				
16 Real estate - Commercial .....				
17 Real estate - Other .....				
18 Collectibles .....				
19 Food inventory .....				
20 Drugs and medical supplies .....				
21 Taxidermy .....				
22 Historical artifacts .....				
23 Scientific specimens .....				
24 Archeological artifacts .....				
25 Other ▶ ( SOFTWARE/SUPP ) .....	X	5	3,088,330.	COST
26 Other ▶ ( ) .....				
27 Other ▶ ( ) .....				
28 Other ▶ ( ) .....				

29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part V, Donee Acknowledgement .....	<b>29</b>	0
--	-----------	---

		Yes	No
30a During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? .....	<b>30a</b>		X
b If "Yes," describe the arrangement in Part II.			
31 Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions? .....	<b>31</b>	X	
32a Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions? .....	<b>32a</b>		X
b If "Yes," describe in Part II.			
33 If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.			

**Part II** **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS.

Multiple horizontal lines for data entry.

**SCHEDULE O  
(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Supplemental Information to Form 990 or 990-EZ**

Complete to provide information for responses to specific questions on  
Form 990 or 990-EZ or to provide any additional information.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for the latest information.

OMB No. 1545-0047

**2021**

Open to Public  
Inspection

Name of the organization

PATH

Employer identification number

91-1157127

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

PATH IS A GLOBAL NONPROFIT DEDICATED TO ACHIEVING HEALTH EQUITY. WITH  
MORE THAN 40 YEARS OF EXPERIENCE FORGING MULTISECTOR PARTNERSHIPS, AND  
WITH EXPERTISE IN SCIENCE, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS  
OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP INNOVATIVE SOLUTIONS  
TO THE WORLD'S MOST PRESSING HEALTH CHALLENGES.

FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS:

CENTER OF DIGITAL AND DATA EXCELLENCE  
PATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH  
EQUITY. IN 2021, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED  
COUNTRY-LED DIGITAL HEALTH TRANSFORMATION. FOR EXAMPLE, WORK CONTINUED  
ON THE DATA USE PARTNERSHIP, A BILL & MELINDA GATES FOUNDATION-FUNDED  
PROJECT WHERE PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS  
HEALTH INFORMATION SYSTEMS. THROUGH THIS PROJECT, THE GOVERNMENT  
ENDORSED A NEW HEALTH ENTERPRISE ARCHITECTURE, AN IMPORTANT STEP TO  
ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE  
PROJECT LAUNCHED AN IMPROVED E-LEARNING PLATFORM THAT STREAMLINES AND  
STANDARDIZES E-LEARNING MODULES TO MAKE IT EASIER TO TRACK HEALTH  
WORKER CREDENTIALS AND SCHOOL RECORDS.

THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE  
GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA  
FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - TO DEVELOP A MODEL

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Schedule O (Form 990) 2021

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA.

BACKED BY A U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO \$120 MILLION, DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES, WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES.

PATH, WITH U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING THE OVERALL HEALTH INFORMATION SYSTEM SUPPORT COMPONENT OF THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM THAT PARTNERS WITH COUNTRIES TO SUPPORT THEM IN BUILDING LASTING DIGITAL HEALTH CAPACITY. IN 2021, THE TEAM RECEIVED APPROVAL FOR OUR SECOND-YEAR WORK PLAN AND BUDGET, ENABLING WORK TO BEGIN ON STRENGTHENING HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN COTE D'IVOIRE, ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, VIETNAM, AND ZAMBIA.

IN 2021, PATH SUPPORTED THE LAUNCH OF THE DIGITAL HEALTH APPLIED LEADERSHIP PROGRAM, A YEAR-LONG TRAINING THAT ENHANCES PARTICIPANTS' CAPACITY TO SUCCESSFULLY LEAD AND EXECUTE DIGITAL HEALTH PROGRAMS. DESIGNED WITH A COMPREHENSIVE LEADERSHIP CURRICULUM FOR A DIVERSE COHORT OF LEARNERS, THE PROGRAM CONSISTS OF CORE ONLINE COURSES, WORKSHOPS, INSTRUCTION FROM TUTORS, AND GUIDANCE FOR PLANNING AND DELIVERING A PROJECT TO BUILD DIGITAL HEALTH CAPACITY ACROSS

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

PARTICIPATING COUNTRIES.

PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS,  
INCLUDING TRANSFORM HEALTH, WHICH SUPPORTS THE DEVELOPMENT OF HEALTH  
DATA GOVERNANCE PRINCIPLES; THE LANCET/FINANCIAL TIMES JOINT  
COMMISSION, WHICH RELEASED ITS REPORT ON GOVERNING HEALTH FUTURES 2030;  
AND THE DIGITAL CONNECTED CARE COALITION.

DIAGNOSTICS

PATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO  
HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH  
OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.

IN 2021, OUR PIONEERING WORK SUPPORTED THE ADVANCEMENT OF AFFORDABLE,  
RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE  
DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES;  
SECURING REGULATORY APPROVAL; CONDUCTING PERFORMANCE EVALUATIONS AND  
CLINICAL STUDIES TO INFORM PATIENT CARE; AND PUBLISHING 18  
PEER-REVIEWED ARTICLES.

IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE  
DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND  
SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS).  
THIS INCLUDED DEVELOPING MULTIPLE PUBLICLY AVAILABLE INTERACTIVE  
COVID-19 DIAGNOSTIC DASHBOARDS TO SUPPORT DATA-DRIVEN PRODUCT SELECTION  
AND PROCUREMENT DECISIONS; CREATING A COVID-19 SAMPLE REPOSITORY TO  
SUPPORT DEVELOPERS IN ACCESSING CLINICAL SAMPLES FOR RESEARCH AND  
DEVELOPMENT; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN BRAZIL, INDONESIA, MALAWI, NEPAL, AND PAKISTAN TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN WASTEWATER; AND CONDUCTING CLINICAL AND OPERATIONAL STUDIES TO ENSURE THAT COVID-19 POINT-OF-CARE TESTS ARE AN EFFECTIVE MEANS OF COMBATTING COVID-19 IN SETTINGS WHERE LABORATORY RESULTS ARE DELAYED OR UNAVAILABLE.

IN MAY 2021, THE SD BIOSENSOR STANDARD G6PD TEST RECEIVED REGULATORY APPROVAL FROM THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA). PATH HELPED GUIDE THE TEST THROUGH PRODUCT DEVELOPMENT AND CLINICAL EVIDENCE GENERATION FOR SUBMISSION TO THE TGA. THIS IS THE FIRST POINT-OF-CARE TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY THAT CAN SUPPORT SAFE ACCESS TO THE CURRENTLY AVAILABLE DRUGS FOR PLASMODIUM VIVAX MALARIA.

IN COLLABORATION WITH THE UNIVERSITY OF QUEENSLAND'S PROTEIN EXPRESSION FACILITY, PATH ADVANCED THE COMMERCIALIZATION OF HIGHLY SPECIFIC AND SENSITIVE MALARIA ANTIGEN REAGENTS FOR IMMUNOLOGICAL TESTS. THESE NEWLY AVAILABLE CUSTOM PROTEINS WILL FACILITATE DEVELOPMENT AND PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, SPECIES-SPECIFIC MALARIA DIAGNOSTICS. THE DIAGNOSTICS TEAM CONTINUED TO MANAGE A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED SIX INFORMATION-SHARING WEBINARS.

IN COLLABORATION WITH THE U.K. NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 14 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW-COST,

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

SEROTYPE-SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.

MEDICAL DEVICES AND HEALTH TECHNOLOGIES

THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LMICS. FOR EXAMPLE, IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE. IN 2021, THE ELLAVI UBT'S AVAILABILITY GREW TO 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN 7 LATIN AMERICAN COUNTRIES, BRINGING THE GLOBAL TOTAL TO 39 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE.

PATH CONTINUED TO SUPPORT INCLUSIVE INNOVATION, HIRING ADDITIONAL DESIGN AND INNOVATION SPECIALISTS IN AFRICA, WHICH ALLOWED THE LIVING LABS INITIATIVE TO CO-CREATE WITH APPROXIMATELY 1,000 FRONTLINE HEALTH WORKERS AND COMMUNITY MEMBERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM FOR MEASLES, RUBELLA, AND COVID-19 VACCINES.

FINALLY, WE CONVENED A GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND U.S. DECISION-MAKERS. WE ALSO PRODUCED AND SHARED GLOBAL COLD CHAIN MODELING DATA FOR COVID-19 VACCINES ACROSS 92

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

ADVANCED MARKET COMMITMENT COUNTRIES. TO ADDRESS THE URGENT NEED FOR A COVID-19 VACCINE THAT IS THERMOSTABLE AND NEEDLE-FREE, THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A FREEZE-DRIED FORMULATION OF AN MRNA VACCINE SUITABLE FOR ORAL AND PARENTERAL ADMINISTRATION.

MARKET DYNAMICS

PATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING, AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS. IN 2021, OUR LARGEST AREAS OF WORK WERE:

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:

(1) IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS IN LMICS. AS PART OF THAT WORK, WE SUPPORTED OUR GOVERNMENT PARTNERS IN THE DEVELOPMENT AND EXECUTION OF COMPREHENSIVE RESPIRATORY CARE PLANS TO MEET THE DEMANDS OF COVID-19. BEYOND THE PANDEMIC RESPONSE, WE ALSO HELPED PRIORITIZE AND IMPROVE ACCESS TO OXYGEN THERAPY AND OTHER ESSENTIAL RESPIRATORY CARE EQUIPMENT AS AN INTEGRAL PART OF NATIONAL AND GLOBAL HEALTH SYSTEMS STRENGTHENING. IN INDIA, KENYA, SENEGAL, AND TANZANIA, WE ADVANCED ACCESS TO AFFORDABLE AND APPROPRIATE TOOLS SUCH AS PULSE OXIMETRY AND ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHMS TO HELP HEALTH CARE WORKERS IDENTIFY CRITICALLY ILL CHILDREN AND REFER THEM FOR TREATMENT WITHOUT DELAY.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

(2) SUPPORTING INTRODUCTION AND SCALE-UP OF MALARIA HEALTH PRODUCTS. THROUGH OUR ROLE IN THE PARTNERSHIP FOR VIVAX ELIMINATION, WE CONTINUED TO FOSTER ACCESS TO CRITICAL MALARIA DRUGS AND DIAGNOSTICS FOR ADULTS AND CHILDREN ACROSS 15 MALARIA-ENDEMIC COUNTRIES.

EPIDEMIC PREPAREDNESS AND RESPONSE

PATH'S EPIDEMIC PREPAREDNESS AND RESPONSE TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. UNDER THE USAID DISCOVERY & EXPLORATION OF EMERGING PATHOGENS - VIRAL ZOOSES PROJECT, THE TEAM SUPPORTED GLOBAL DATA MANAGEMENT AND SHARING AND LED PROJECT START-UP IN SENEGAL AND VIETNAM. THE TEAM WORKED AS A MAJOR SUBGRANTEE ON THE USAID INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT AND LED IN SENEGAL, TANZANIA, UGANDA, AND VIETNAM. IN THESE COUNTRIES, OUR CROSS-ORGANIZATIONAL IMPACT TEAM ALSO SUPPORTED COVID-19 OUTBREAK RESPONSE ACTIVITIES, WHILE REMAINING AT THE FOREFRONT OF ANTIMICROBIAL RESISTANCE AND GENOMIC SURVEILLANCE IN VIETNAM, IN PARTICULAR. WITH SUPPORT FROM THE U.S. CDC, PATH WORKED WITH NATIONAL LEADERS IN MYANMAR, SENEGAL, TANZANIA, AND VIETNAM TO BUILD CAPACITY FOR EPIDEMIC PREPAREDNESS AND RESPONSE. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING DIAGNOSTIC NETWORK CAPABILITIES, AND LINKING THIS WORK WITH THE DEVELOPMENT OF NEW DIAGNOSTICS, VACCINES, AND DATA TOOLS.

MALARIA AND NEGLECTED TROPICAL DISEASES

PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS AROUND THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE.

IN 2021, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. FOR INSTANCE, MACEPA PROVIDED MATHEMATICAL MODELING AND DATA ANALYTICS SUPPORT, INCLUDING ESTIMATING THE CATCHMENT POPULATION OF EACH HEALTH FACILITY IN ZAMBIA AND USING HUMAN MIGRATION DATA TO CAPTURE POPULATION FLOW AT THE DISTRICT LEVEL IN ETHIOPIA. MACEPA ALSO CONDUCTED EXPLORATORY ACTIVITIES IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC) AND NIGERIA (E.G., ANALYSES OF CURRENT MALARIA SURVEILLANCE SYSTEMS) TO INFORM TECHNICAL ASSISTANCE NEEDS AND RECOMMENDATIONS FOR THOSE GEOGRAPHIES.

THE PAMO PLUS PROJECT, FUNDED BY THE U.S. PRESIDENT'S MALARIA INITIATIVE (PMI), PROVIDED TECHNICAL AND MATERIAL ASSISTANCE TO THE ZAMBIA MINISTRY OF HEALTH (MOH) IN MALARIA CASE MANAGEMENT, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, DISEASE SURVEILLANCE, AND DATA MANAGEMENT AND USE. WORK IN 2021 INVOLVED MENTORING HEALTH WORKERS IN THE PROJECT'S FOUR FOCUS PROVINCES ON ADHERENCE TO MALARIA CASE MANAGEMENT STANDARDS AS WELL AS TRAINING, DEPLOYING, AND SUPPORTING COMMUNITY HEALTH WORKERS WHO TEST AND TREAT MALARIA AT THE COMMUNITY LEVEL. ADDITIONALLY, PAMO PLUS WORKED WITH THE ZAMBIA NURSING AND MIDWIFERY COUNCIL TO INTEGRATE MALARIA IN PREGNANCY TRAINING INTO THE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

NURSING COLLEGE CURRICULUM, AND TRAINED ANTENATAL CARE PROVIDERS AND SAFE MOTHERHOOD ACTION GROUP MEMBERS ON THE MALARIA IN PREGNANCY GUIDELINES. PAMO PLUS SUPPORTED THE DEVELOPMENT OF COMMUNITY ENGAGEMENT PLANS, ORIENTED COMMUNITY CHANGE AGENTS, CONDUCTED DATA QUALITY AUDITS, AND TRAINED MOH STAFF IN DATA MANAGEMENT AND MENTORSHIP. PAMO PLUS CONTINUED IMPLEMENTING A MALARIA PRE-ELIMINATION PROGRAM, CONDUCTING RESEARCH IN LOW-BURDEN DISTRICTS OF EASTERN PROVINCE, ZAMBIA.

IN 2021, PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS WITH OUR PARTNERS UNDER PMI VECTORLINK, USAID'S FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND), WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB). WE COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND U.K.-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM.

PATH ALSO LED A USAID INITIATIVE TO SUPPORT MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN NATIONAL POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION.

IN SENEGAL AND THE GAMBIA, PATH CONTINUED TO INTEGRATE MALARIA INTO THE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

SCOPE OF NATIONAL EMERGENCY OPERATIONS CENTERS (EOCS). IN SENEGAL, WE SUPPORTED THE MOH TO CREATE AND RESOURCE REGIONAL EOC-MALARIA UNITS. WITH A REGIONAL PRESENCE, THE EOC CAN MORE RAPIDLY RESPOND TO POTENTIAL PUBLIC HEALTH THREATS. THIS WORK HAS STRENGTHENED CROSS-BORDER COLLABORATION BETWEEN THE GAMBIA AND SENEGAL ON EMERGENCY PREPAREDNESS AND RESPONSE AND MALARIA INTERVENTIONS.

PATH'S LABORATORY TEAM AT THE NATIONAL MALARIA ELIMINATION CENTER IN LUSAKA, ZAMBIA - A TEAM TASKED WITH GENOTYPING PLASMODIUM PARASITES TO LOOK FOR MARKERS OF RESISTANCE TO COMMON MALARIA TREATMENTS - ALSO APPLIED THEIR EXPERTISE TO SARS-COV-2. IN 2021, THEY WORKED WITH THE UNIVERSITY OF ZAMBIA'S SCHOOL OF VETERINARY MEDICINE TO SEQUENCE INFECTIONS AND MAP THE RISE AND FALL OF DIFFERENT COVID-19 VARIANTS. THE TEAM RECEIVED FUNDING TO EXPAND THEIR FOCUS FROM GENERATING DATA TO STRENGTHENING THE SEQUENCING SKILLS WITHIN THE ZAMBIAN GOVERNMENT.

THE VIVACTION PROJECT WORKS TO CATALYZE ADOPTION AND EVENTUAL SCALE-UP OF PLASMODIUM VIVAX TOOLS. IN ETHIOPIA, PATH IS STUDYING WHETHER IT IS OPERATIONALLY FEASIBLE TO PROVIDE OPTIMIZED RADICAL CURE TREATMENT TO P. VIVAX PATIENTS WHO ARE ELIGIBLE BASED ON TREATMENT GUIDELINES. IN 2021, PATH HELD MEETINGS WITH LOCAL PARTNER ARMAUER HANSEN RESEARCH INSTITUTE TO DISCUSS PROJECT ACTIVITIES.

IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE IN THE STATE OF UTTAR PRADESH, SUPPORTING THE NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAM TO ADDRESS DENGUE AND MALARIA THROUGH SKILLS STRENGTHENING, OUTBREAK INVESTIGATION, AND DATA MANAGEMENT. PATH PROVIDED TECHNICAL SUPPORT FOR SAFE AND SUCCESSFUL MASS DRUG

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

ADMINISTRATION CAMPAIGNS AS WELL AS MORBIDITY MANAGEMENT AND DISABILITY

PREVENTION SERVICES ACROSS 50 LYMPHATIC FILARIASIS-ENDEMIC DISTRICTS.

IN THE STATE OF BIHAR, PATH SUPPORTED IMPLEMENTATION OF A JAPANESE

ENCEPHALITIS VACCINATION CAMPAIGN.

EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK

IN 2021, THE EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK (ECDAN), HOSTED

BY PATH, CONTINUED TO ADVOCATE FOR YOUNG CHILDREN AND THEIR CAREGIVERS.

ECDAN SUPPORTED AND FACILITATED SEVERAL COLLABORATIVE INITIATIVES,

INCLUDING LAUNCH OF THE GLOBAL CHILDCARE CAMPAIGN AND - WITH OUR

PARTNERS, THE WORLD HEALTH ORGANIZATION (WHO), UNICEF, PARTNERSHIP FOR

LIFELONG HEALTH, AND GLOBAL PARTNERSHIP TO END VIOLENCE AGAINST

CHILDREN - LAUNCH OF THE GLOBAL INITIATIVE TO SUPPORT PARENTS. ECDAN

CONNECTED AND ALIGNED THE GLOBAL COMMUNITY THROUGH CALLS TO ACTION,

JOINT STATEMENTS, AND COMMUNITIES OF PRACTICE AND ACCELERATED LEARNING

AND KNOWLEDGE EXCHANGE THROUGH WEBINARS AND TWO PLATFORMS: ECD CONNECT

AND ECD KNOWLEDGE GATEWAY. ECDAN FINALIZED THREE COUNTRY PILOTS TO TEST

THE "COST OF INACTION" METHODOLOGY WITH UNICEF IN BULGARIA AND

MADAGASCAR AND WITH THE UNIVERSITY OF SAO PAULO IN BRAZIL. ECDAN ALSO

WELCOMED OUR FIRST COHORT OF KNOWLEDGE FELLOWS. FIVE FELLOWS (FROM

COLOMBIA, THE PHILIPPINES, SPAIN, UNITED STATES, AND ZAMBIA) COMPLETED

THE PROGRAM, WORKING WITH A MENTOR TO DESIGN AND FINALIZE A KNOWLEDGE

PRODUCT.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:

PRIMARY HEALTH CARE

PATH'S PRIMARY HEALTH CARE (PHC) DEPARTMENT EMPLOYS A COMPREHENSIVE,

ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PHC MODEL THAT ADDRESSES

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL).

WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET

PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. PHC AT PATH IS

COMPOSED OF SIX TEAMS, DESCRIBED BELOW.

MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION

TOGETHER WITH PARTNERS AROUND THE WORLD, PATH'S MATERNAL, NEWBORN, AND

CHILD HEALTH AND NUTRITION (MNCHN) TEAM DEVELOPS, ADAPTS, AND SCALES UP

TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AMONG MOTHERS AND

CHILDREN AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE.

TO ENSURE THAT ALL INFANTS HAVE ACCESS TO HUMAN MILK, PATH FOCUSES ON

BREASTFEEDING PROMOTION, PROVISION OF SPECIALIZED LACTATION SUPPORT FOR

MOTHERS OF SMALL AND SICK NEWBORNS, AVAILABILITY OF SAFE DONOR MILK

THROUGH LOCAL HUMAN MILK BANKS, AND UPTAKE AND USE OF GLOBAL STANDARDS

FOR HUMAN MILK BANKING. USING HUMAN-CENTERED DESIGN, WE CONTINUED

CREATING A DIGITAL ADAPTATION KIT FOR OPTIMAL NEWBORN FEEDING AND THE

PROVISION OF LACTATION SUPPORT, WHICH IS BEING DEVELOPED IN KENYA AS A

GLOBAL GOOD FOR ALL SETTINGS. PATH CONTINUED SUPPORTING ARIADNE LABS AS

A SUBJECT MATTER EXPERT AND PERFORMED A FEASIBILITY ASSESSMENT IN

INDIA, MALAWI, AND TANZANIA ON THE USE OF DONOR HUMAN MILK FOR

LOW-BIRTHWEIGHT INFANTS. THESE FINDINGS ARE BEING DISSEMINATED GLOBALLY

AND THROUGH MULTIPLE PEER-REVIEWED PUBLICATIONS.

IN GHANA, PATH IS LEADING A FOUR-YEAR EFFORT, ADVANCED NEWBORN CARE IN

GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE

PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS. IN 2021,

MEBCI 2.0 ENGAGED WITH THE GHANA HEALTH SERVICE TO OPERATIONALIZE ITS

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

NEWBORN ACTION PLAN, MOBILIZE REGIONAL STAKEHOLDERS AND RESOURCES, AND

DRIVE ADVOCACY AND POLICY ACTION.

THROUGH THE NEOLENS PROJECT, PATH DOCUMENTED COUNTRY-LEVEL JOURNEYS IN

ESTABLISHING IN-PATIENT CARE FOR SMALL AND SICK NEWBORNS IN

LOW-RESOURCE SETTINGS. TO SHOWCASE LESSONS LEARNED IN ETHIOPIA, INDIA,

MALAWI, AND RWANDA, WE CREATED CASE STUDIES FOR EACH COUNTRY AND

PARTNERED WITH MASS DESIGN GROUP TO DEVELOP AN INTERACTIVE, VIRTUAL

EXPERIENCE.

FOLLOWING A PATH PROJECT THAT DOCUMENTED UPTAKE OF 14 KEY MNCHN ASSETS

IN 81 COUNTDOWN TO 2030 COUNTRIES, IN 2021 PATH CONDUCTED A SUBNATIONAL

INQUIRY IN FIVE FOCUS COUNTRIES ON THE INHERENT BARRIERS AND ENABLERS

TO SCALE-UP OF THESE COMMODITIES. WE DEVELOPED COMPLEMENTARY

INTERACTIVE DASHBOARDS TO PROVIDE THE DATA IN A USER-FRIENDLY

INTERFACE.

IN COLLABORATION WITH THE GHANA HEALTH SERVICE AND WITH FUNDING FROM

THE PFIZER FOUNDATION, PATH INITIATED THE INTEGRATED ANTENATAL CARE

PROJECT IN THE BONO EAST REGION OF GHANA. THE PROJECT AIMS TO AVERT

INFECTIOUS DISEASE MORTALITY AND MORBIDITY IN NEONATES AND MOTHERS BY

IMPLEMENTING AN IMPROVED, COMPREHENSIVE INFECTIOUS DISEASE SCREENING

PROGRAM DURING PREGNANCY.

ALSO IN 2021, MNCHN STAFF SERVED GLOBALLY IN LEADERSHIP ROLES RELATED

TO COVID-19 AND THE PROTECTION OF WOMEN AND CHILDREN. WE PARTICIPATED

IN GLOBAL TECHNICAL WORKING GROUPS, PRESENTED (MOSTLY VIRTUALLY) AT KEY

GLOBAL AND NATIONAL MEETINGS, AND AUTHORED AND CONTRIBUTED TO

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MNCHN.

RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. TOGETHER WITH PATH'S CLIMATE CHANGE COMMUNITY OF PRACTICE, PATH'S NUTRITION TEAM CONTINUED TO ADVOCATE FOR SUSTAINABLE CLIMATE-FRIENDLY ALTERNATIVES, SUCH AS CULTURED PROTEINS AND EDIBLE INSECTS. AS A REFLECTION OF OUR EXPERTISE, PATH LEADS THE BIOMARKER COLLECTION AND ANALYSIS COMPONENTS OF THE DEMOGRAPHIC HEALTH SURVEY CONDUCTED IN COUNTRIES AROUND THE WORLD. FINALLY, PATH CONTINUED OUR WORK ON THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT OF MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH.

EARLY CHILDHOOD DEVELOPMENT

IN 2021, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). FOR EXAMPLE, WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO SCALE UP ECD SERVICE PROVISION AS AN ESSENTIAL COMPONENT OF BASIC HEALTH CARE AND INTRODUCED INTEGRATED ECD SERVICE DELIVERY INTO ADDITIONAL SUBNATIONAL GEOGRAPHIES. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. WITH A CONSTELLATION OF PARTNERS, PATH FACILITATED COLLECTIVE ACTION ACROSS

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

MULTIPLE SECTORS AT NATIONAL AND SUBNATIONAL LEVELS TO PROMOTE ECD THROUGH ENHANCED PLANNING, COORDINATION, AND RESOURCING.

HEALTH SYSTEMS

THE HEALTH SYSTEMS TEAM SERVES AS AN ORGANIZING MECHANISM FOR PATH'S PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS. BOTH WITHIN PATH AND IN COLLABORATION WITH EXTERNAL PARTNERS, THE TEAM LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES INTERVENTION SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2021, MAJOR ACTIVITIES INCLUDED (1) COMPLETION OF A FOUR-YEAR PROSPECTIVE EVALUATION OF THE GLOBAL FUND'S INVESTMENTS IN THE DRC, GUATEMALA, SENEGAL, AND UGANDA; (2) LEADING MONITORING, EVALUATION, AND LEARNING WITHIN USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PORTFOLIO ACROSS SEVERAL COUNTRIES IN AFRICA AND SOUTHEAST ASIA; AND (3) EVALUATION OF AN INNOVATION TO INCREASE HIV PRE-EXPOSURE PROPHYLAXIS UPTAKE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN ZIMBABWE.

HIV, TUBERCULOSIS, AND VIRAL HEPATITIS AS COVID-19 CONTINUED TO DISRUPT ACCESS TO ESSENTIAL HEALTH SERVICES, PATH'S HIV, TUBERCULOSIS (TB), AND VIRAL HEPATITIS TEAM FOCUSED ON ADVANCING PERSON-CENTERED HEALTH CARE ACROSS AFRICA, CENTRAL ASIA, AND SOUTHEAST ASIA FOR GENERAL, KEY, AND PRIORITY POPULATIONS. METHODS INCLUDED PROMOTING INTEGRATED SERVICE DELIVERY MODELS, ACCELERATING SELF-CARE INITIATIVES, AND LEVERAGING DIGITAL HEALTH TOOLS TO ENSURE EQUITABLE AND HIGH-QUALITY ACCESS TO HEALTH SERVICES.

PATH, WITH FUNDING FROM UNITAID THROUGH THE STAR-III PROJECT, CONTINUED

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

TO ACCELERATE ACCESS TO HIV SELF-TESTING (HIVST) IN INDIA, INDONESIA,  
AND UGANDA BY CONDUCTING ASSESSMENTS TO INFORM DEVELOPMENT OF NEW HIVST  
DISTRIBUTION MODELS AND NATIONAL POLICIES AND GUIDELINES. IN 2021, THE  
PROJECT SUPPORTED THE DISTRIBUTION OF MORE THAN 150,000 HIVST KITS AND  
TRAINED MORE THAN 750 PROVIDERS ON HIVST SERVICES. PATH ALSO RECEIVED  
FUNDING TO ADVANCE SELF-TESTING FOR HEPATITIS C IN INDIA AND VIETNAM  
AND SELF-TESTING FOR COVID-19 IN BRAZIL, INDIA, SOUTH AFRICA, AND  
UGANDA, WITH THIS YEAR'S EFFORTS FOCUSED ON ORIENTING STAKEHOLDERS AND  
PREPARING FOR IMPLEMENTATION.

AS A PARTNER ON THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END  
TB PROJECT, PATH WORKED TO ESTABLISH A GLOBAL MARKET FOR DIGITAL  
ADHERENCE TECHNOLOGIES (DATS). WE IMPLEMENTED RESEARCH IN UKRAINE ON  
THE USE OF DATS AND SUCCESSFULLY ADVOCATED WITH THE UKRAINIAN  
GOVERNMENT FOR SCALE-UP OF DATS DURING WAR AND AMONG DISPLACED PERSONS.

IN PARTNERSHIP WITH THE TB ALLIANCE, PATH WORKED TO ADVANCE A SHORTER  
TREATMENT (BEDAQUILINE, PRETOMANID, AND LINEZOLID, KNOWN AS BPAL) FOR  
MULTIDRUG-RESISTANT TB, DEVELOPING A ROAD MAP TO INTRODUCE BPAL IN PERU  
AND UKRAINE AS WELL AS FACILITATING A COSTING STUDY OF BPAL IN UKRAINE.

IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT IN  
HAUT-KATANGA (IHAP-HK), PATH TESTED AND EXPANDED PERSON-CENTERED  
APPROACHES FOR ENHANCED CARE, TREATMENT SUPPORT, AND VIRAL LOAD  
MONITORING. THE PROJECT CO-CREATED AN ELECTRONIC CLIENT FEEDBACK SYSTEM  
WITH FACILITY PROVIDERS AND ASSOCIATIONS OF PEOPLE LIVING WITH HIV  
(PLHIV) AND THEN TESTED THE SYSTEM AT SIX FACILITIES. IMPLEMENTATIONS  
BASED ON THE FEEDBACK RESULTED IN SHORTER WAIT TIMES FOR CLIENTS AND

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

FEWER INSTANCES OF STIGMA AND DISCRIMINATION. IHAP-HK ALSO CO-ADAPTED,  
 WITH ADOLESCENTS AND YOUNG PEOPLE, KENYA'S OPERATION TRIPLE ZERO  
 APPROACH FOR THE DRC CONTEXT. THIS LED TO THE CREATION OF ADDITIONAL  
 COMMUNITY SUPPORT GROUPS FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE  
 FOCUSED ON PROMOTING ADHERENCE TO TREATMENT AND CLINICAL APPOINTMENTS,  
 WITH THE GOAL OF VIRAL SUPPRESSION. THE PROJECT ALSO TESTED  
 COLLABORATIVE CASE MANAGEMENT AMONG HEALTH WORKERS, PEER EDUCATORS, AND  
 CASE MANAGERS FOR CHILDREN LIVING WITH HIV TO PROVIDE ENHANCED  
 ADHERENCE SUPPORT SERVICES, AGAIN TO HELP ACHIEVE VIRAL SUPPRESSION.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:  
 IN WESTERN KENYA, PATH SUCCESSFULLY CLOSED OUT THE PEPFAR-FUNDED AFYA  
 ZIWANI PROJECT. OVER THE PROJECT LIFETIME, 1,586,802 PEOPLE WERE TESTED  
 FOR HIV, OF WHICH 25,569 WERE DIAGNOSED WITH HIV AND LINKED TO CARE AND  
 TREATMENT. IN MID-2021, PATH TRANSITIONED THE PROGRAMMING TO TWO NEW  
 INITIATIVES: (1) A COMPREHENSIVE PACKAGE OF HEALTH, SOCIAL, AND  
 ECONOMIC STRENGTHENING SERVICES FOR CHILDREN, ADOLESCENTS, AND YOUNG  
 PEOPLE THROUGH THE PEPFAR-FUNDED NURU YA MTOTO PROJECT, FOR WHICH PATH  
 IS PRIME; AND (2) HIGH-QUALITY CLINICAL HIV AND TB/HIV SERVICES FOR  
 PEOPLE LIVING WITH OR AT RISK OF HIV THROUGH THE PEPFAR-FUNDED BORESHA  
 JAMII PROJECT, FOR WHICH PATH IS A KEY SUBPARTNER LEADING THE CLINICAL  
 WORK. PATH ALSO LED THE CHAK A CHAKA PROJECT, WHICH STRENGTHENS  
 ECONOMIC SKILLS AMONG YOUNG WOMEN IN KISUMU, HOMA BAY, AND MIGORI  
 COUNTIES TO REDUCE HIV RISK AND VULNERABILITY. IN 2021, PATH HELPED  
 1,225 YOUNG WOMEN BUILD SAVINGS AND ENTREPRENEURIAL SKILLS THROUGH  
 ACCESS TO BUSINESS DEVELOPMENT TRAININGS AND INSURANCE FUNDS.

IN INDIA, THROUGH THE U.S. CDC-FUNDED STRENGTHENING STRATEGIC

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

INFORMATION MANAGEMENT SYSTEMS PROJECT, PATH CONTINUED TO SUPPORT THE NATIONAL AIDS CONTROL PROGRAM AT THE STATE AND DISTRICT LEVEL IN MUMBAI AND ANDHRA PRADESH AS WELL AS NATIONALLY TO FURTHER STREAMLINE DATA REPORTING SYSTEMS AND ENHANCE DATA USE FOR PROGRAM IMPROVEMENT AND PLANNING. AMONG OTHER ACTIVITIES, WE CREATED SITE-LEVEL SYSTEMS TO IMPROVE FOLLOW-UP WITH CLIENTS, DEPLOYED A MONTHLY DISTRICT-LEVEL PLANNING PROCESS IN ANDHRA PRADESH TO IMPROVE HIV TESTING AND LINKAGES TO SERVICE, AND CREATED NATIONAL-LEVEL DASHBOARDS TO BETTER MONITOR HIV PROGRAM PERFORMANCE AGAINST EPIDEMIC CONTROL INDICATORS.

IN SUPPORT OF TB PROGRAMMING IN INDIA, PATH INTRODUCED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TREATMENT. WITH SUPPORT FROM USAID, PATH FACILITATED A NEEDS ASSESSMENT FOR TECHNICAL SUPPORT UNITS TO FOSTER LOCAL PRIVATE-SECTOR ENGAGEMENT ACROSS FIVE INDIAN STATES. PATH ALSO SUPPORTED REVISIONS AND UPDATES TO TB CONTROL STANDARDS IN PARTNERSHIP WITH WHO AND THE NATIONAL TB PROGRAM.

IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED ERADICATE TB PROJECT, WHICH SCREENED 1,967,914 INDIVIDUALS FOR SYMPTOMS OF TB, AMONG WHOM 223,337 (11%) WERE PRESUMED TO HAVE TB. SAMPLES FROM 200,899 (90%) OF THOSE WERE THEN TESTED IN THE LABORATORY, RESULTING IN 9,872 (5%) CONFIRMED TB CASES. OF THESE, 9,521 (96%) WERE SUCCESSFULLY INITIATED ON TREATMENT. THE PROJECT ALSO STRENGTHENED THE LABORATORY NETWORK TO MORE EFFICIENTLY AND EFFECTIVELY DIAGNOSE AND MONITOR PEOPLE WITH TB. AN EXTERNAL QUALITY ASSESSMENT SHOWED THAT 90% OF HEALTH FACILITY LABORATORIES ACHIEVED 95% CORRECT RESULTS. THE PROJECT CONTINUED TO TRAIN FRONTLINE HEALTH CARE WORKERS IN THE SIX SUPPORTED PROVINCES ON

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

CHILDHOOD TB DETECTION AND DRUG-RESISTANT TB CASE MANAGEMENT.

IN TANZANIA, THE USAID-FUNDED IDDS PROJECT SUPPORTED KEY FUNCTIONS AT THE CENTRAL TB REFERENCE LABORATORY, FACILITATED REPORTING FROM SITES USING THE GENEXPERT PLATFORM, COMPLETED AN ASSESSMENT OF THE TB DIAGNOSTIC NETWORK, AND PREPARED FOR INTRODUCTION OF NEW DIAGNOSTIC METHODS. THROUGH THIS PROJECT IN VIETNAM, PATH CONTINUED TO SUPPORT THE NATIONAL TB PROGRAM BY ASSESSING PROGRESS ON THE "DOUBLE X" STRATEGY (CHEST X-RAY AND GENEXPERT TEST), SUPPORTING THE APPLICATION OF ARTIFICIAL INTELLIGENCE FOR READING CHEST X-RAYS, AND PERFORMING ANALYSES TO IMPROVE SPECIMEN TRANSPORT SYSTEMS AND DIAGNOSTIC ACCESS.

ALSO IN VIETNAM, THE USAID/PATH HEALTHY MARKETS PROJECT INTRODUCED NEW HIV PRODUCTS TO OPTIMIZE CHOICE FOR CLIENTS, SUPPORTED THE DEVELOPMENT OF CRITICAL NEW POLICIES (INCLUDING A FIRST-EVER HIV PRIVATE-SECTOR ENGAGEMENT PLAN), AND RAPIDLY PIVOTED KEY POPULATION PLATFORMS TO DELIVER LIFESAVING COVID-19 AND HIV CARE DURING VIETNAM'S SEVERE FOURTH SURGE OF COVID-19. IN DECEMBER, THE TEAM TRANSITIONED THE PROJECT TO USAID/PATH STEPS, A FIVE-YEAR PEPFAR-FUNDED INITIATIVE THAT BUILDS ON THE ACHIEVEMENTS OF HEALTHY MARKETS.

IN PARTNERSHIP WITH THE HEPATITIS FUND, PATH LAUNCHED INTEGRATED AND COMMUNITY-BASED HIV AND VIRAL HEPATITIS SCREENING AT 27 HEALTH FACILITIES IN VIETNAM, TESTING MORE THAN 11,000 PEOPLE FOR HEPATITIS B AND C AND ENROLLING MORE THAN 500 ON TREATMENT. WE ALSO PARTNERED WITH THE MOH TO PROTOTYPE A DIGITALIZED VIRAL HEPATITIS HEALTH INFORMATION AND TRACKING SYSTEM.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN, PATH PROVIDED CLINICAL EXPERTISE TO CREATE AND REVISE NATIONAL GUIDELINES AND PROTOCOLS FOR DRUG-SENSITIVE AND DRUG-RESISTANT TB, DEVELOPED PLANS FOR A CLINICAL AUDIT, AND SUPPORTED OPERATIONS RESEARCH AND SCALE-UP PLANNING FOR NEW TB REGIMENS UNDER THE USAID ELIMINATING TB IN CENTRAL ASIA PROJECT.

IN UKRAINE, PATH CONTINUED TO LEAD THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. WE PILOTED INNOVATIVE INTERVENTIONS THAT WILL ULTIMATELY BE TRANSITIONED TO GOVERNMENT LEADERSHIP, INCLUDING MEDICATION-ASSISTED THERAPY, PROVISION OF PSYCHOSOCIAL AND HIV SERVICES FOR PRE-TRIAL DETAINEES, AND INDEX CASE TESTING FOR CONTACTS OF DETAINEES NEWLY DIAGNOSED WITH HIV.

PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2021, STBCEU SUCCESSFULLY ADVOCATED FOR THE INTRODUCTION OF STOOL TESTING AS THE PREFERRED METHOD OF TB DIAGNOSIS AMONG CHILDREN, PILOTED MOBILE X-RAY SCREENINGS, IMPROVED ALGORITHMS FOR ACTIVE CASE FINDING AMONG POPULATIONS AT RISK FOR TB, AND PROVIDED TB EDUCATION THROUGH NATIONAL NEWS PROGRAMS.

NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF EFFORTS TO PREVENT, DETECT, AND TREAT NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

IN 2021, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LMICS. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT AND IMPLEMENTATION OF A FORECASTING PROGRAM FOR NCD MEDICINES AND PRODUCTS IN KENYA AND UGANDA.

PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, AND VIETNAM TO BUILD STRONGER PHC SYSTEMS, SUPPLY CHAINS, AND DATA-DRIVEN DECISION-MAKING - ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY.

OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING AND IMPLEMENTATION OF THE NCD NAVIGATOR - A FIRST-OF-ITS-KIND, LOCALLY MANAGED DIGITAL INFORMATION SYSTEM FOR NCD RESOURCE PLANNING AND ALLOCATION - IN 9 OF GHANA'S 16 REGIONS. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT, WHICH FOCUSES ON HYPERTENSION MANAGEMENT AT THE COMMUNITY LEVEL, CONDUCTED MORE THAN 500,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN SENEGAL, PATH ALSO LAUNCHED THE HEALTHY HEART AFRICA PROJECT, WHILE RWANDA AND TANZANIA PREPARED FOR IMPLEMENTATION.

IN KENYA, PATH IMPLEMENTED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MOH BUT CONTINUED TO PROVIDE TECHNICAL ASSISTANCE. AS THE MOH SEEKS TO IMPROVE THE SUPPLY CHAIN IN PREPARATION

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

FOR UNIVERSAL HEALTH COVERAGE, WE BEGAN IMPLEMENTING SEVERAL INNOVATIONS FOR NCDS, SUCH AS A STOCK TRACKER, AN ELECTRONIC MEDICAL RECORD MODULE, AND LAST-MILE DISTRIBUTION OF NCD MEDICINES AND SUPPLIES. PATH ALSO BEGAN IMPLEMENTING AN HIV/HYPERTENSION INTEGRATION PROJECT IN THREE FACILITIES IN WESTERN KENYA TO INCREASE ACCESS TO CARE.

OUR FOCUS IN VIETNAM WAS ON A PHC MODEL THAT USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENINGS AND LINKAGES TO CARE. IN ADDITION, WE CONDUCTED A SUPPLY CHAIN ASSESSMENT TO DETERMINE THE AVAILABILITY AND AFFORDABILITY OF NCD MEDICINES AT THE PHC LEVEL.

PATH ALSO LAUNCHED THE DIABETES CAREPAK IN KENYA AND VIETNAM, AN INNOVATIVE SOLUTION TO BUNDLE THE COMMODITIES NEEDED FOR SAFE ADMINISTRATION OF INSULIN AND OTHER DIABETES SELF-CARE PRODUCTS. EXPANSION INTO MALI, MOZAMBIQUE, TANZANIA, AND UGANDA WAS APPROVED TOWARD THE END OF THE YEAR.

FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:  
SEXUAL AND REPRODUCTIVE HEALTH  
PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE AND GROUNDED IN AN UNDERSTANDING OF THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

DIMENSIONS OF SRH THROUGHOUT THE LIFE CYCLE. WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE CO-DESIGNED WITH AND FOR WOMEN AND GIRLS TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES, REDUCE BARRIERS, AND EXPAND OPTIONS.

PATH IS A LEADER IN THE SELF-CARE MOVEMENT, SUPPORTING INDIVIDUALS AND FAMILIES WHO CHOOSE TO MANAGE THEIR OWN HEALTH. IN SENEGAL, THE MOH, PATH, AND PARTNERS ARE ADVANCING POLICY THROUGH THE SELF-CARE PIONEERS, A COALITION OF CHAMPIONS LEADING THE DEVELOPMENT OF SENEGAL'S SELF-CARE GUIDELINES. THESE WILL BE AMONG THE FIRST NATIONAL SELF-CARE GUIDELINES IN THE WORLD, AND THE FIRST IN FRANCOPHONE AFRICA.

WITH ASSISTANCE FROM PATH AND PARTNERS, COUNTRIES HAVE CONTINUED TO ACCELERATE SCALE-UP OF THE CONTRACEPTIVE INNOVATION, SELF-INJECTION WITH SUBCUTANEOUS DMPA (DMPA-SC). LED BY PATH IN PARTNERSHIP WITH JOHN SNOW, INC., THE DMPA-SC ACCESS COLLABORATIVE IN 2021 PROVIDED TECHNICAL ASSISTANCE TO 20 COUNTRIES AND COLLECTED DATA FROM 11 COUNTRIES SHOWING MORE THAN 315,000 CLIENT SELF-INJECTION VISITS. IN UGANDA, PATH AND THE MOH ARE IMPLEMENTING GROUNDBREAKING PERSON-CENTERED PROGRAMS TO DEMONSTRATE HOW SELF-INJECTION CAN BE OFFERED AT SCALE.

FOR DECADES, PATH HAS BEEN AT THE FOREFRONT OF EVIDENCE-BASED STRATEGIES TO ADDRESS THE INEQUITABLE BURDEN OF CERVICAL CANCER IN LMICS, FROM HUMAN PAPILLOMAVIRUS (HPV) VACCINE RESEARCH AND DELIVERY TO CERVICAL CANCER SCREENING AND TREATMENT. GLOBALLY, PATH HELPED SHAPE STRATEGIES FOR LMICS AS PART OF WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION, AND WE CONTINUE TO PURSUE OPPORTUNITIES FOR SECONDARY PREVENTION (I.E., EARLY DETECTION) INTERVENTIONS.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

IN PERU, PATH IMPLEMENTED A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR THESE SETTINGS. WE PARTNERED WITH THE MOH TO DESIGN AND IMPLEMENT A REAL-TIME DIGITAL PATIENT TRACKING SYSTEM FOR BREAST CANCER DETECTION.

THROUGH THE USAID IMPROVING MARKET PARTNERSHIPS AND ACCESS TO COMMODITIES TOGETHER PROJECT IN MADAGASCAR, PATH AND PUBLIC- AND PRIVATE-SECTOR CHAMPIONS SUPPORTED THE GOVERNMENT TO DEVELOP A STRATEGY FOR A TOTAL MARKET APPROACH TO IMPROVE ACCESS TO HIGH-QUALITY HEALTH PRODUCTS FOR FAMILY PLANNING (FP), MATERNAL AND CHILD HEALTH, AND MALARIA.

IN INDIA, PATH IMPLEMENTED SEVERAL SUPPLY CHAIN STRENGTHENING INITIATIVES TO HELP ENSURE AVAILABILITY OF FP PRODUCTS. WE PILOTED AN INFORMED PUSH MODEL TO REDUCE STOCKOUTS, INTRODUCED KITS FOR LAST-MILE FP AVAILABILITY, DESIGNED A SUPPLY CHAIN MANAGEMENT E-LEARNING COURSE, AND FACILITATED A PARTNERSHIP BETWEEN THE ODISHA STATE GOVERNMENT AND THE INDIA POST FOR FP DELIVERY. WE CONDUCTED A POLICY AND REGULATORY LANDSCAPE FOR PRIVATE-SECTOR FP DELIVERY AND CONTRIBUTED TO INDIA'S FP2030 DRAFT COMMITMENTS ON STRENGTHENING SUPPLY CHAINS.

IN MYANMAR, PATH IS FULFILLING THE GROWING NEED FOR INFORMATION AND SERVICES TO ADDRESS GENDER-BASED VIOLENCE (GBV) AND SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (SRHR) AMID THE CURRENT LOCAL POLITICAL SITUATION AND COVID-19 PANDEMIC. WITH FUNDING FROM WHO, WE INCREASED GBV AWARENESS IN THE PERI-URBAN YANGON MIGRANT COMMUNITY; SUPPORTED WOMEN IN CRISIS WITH FOOD, SHELTER, AND TRANSPORTATION; CONDUCTED A

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

WELL-BEING WORKSHOP AND WEBINAR; AND FACILITATED A 16-DAY SRHR AND GBV  
ACTIVISM CAMPAIGN.

PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH  
SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND  
PRIVATE ENTITIES AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND  
ACCESS TO CRITICAL SRH AND FP SUPPLIES AND SERVICES.

FORM 990, PART III, LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS:  
CENTER FOR VACCINE INNOVATION AND ACCESS  
PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS  
EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE  
VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR  
PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT  
OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF  
CHILD DEATH AND DISEASE WORLDWIDE.

IN 2021, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY  
PROVIDING EXPERTISE TO THE COVAX FACILITY, SUPPORTING VACCINE SUPPLY  
CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE  
MANUFACTURERS, STRENGTHENING CLINICAL RESEARCH CENTER AND COUNTRY  
DELIVERY READINESS, AND TRAINING PHARMACISTS AS VACCINATORS IN GHANA.  
WE ALSO SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND  
PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM  
DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL,  
THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, PATH GUEST EDITED A  
SPECIAL ISSUE OF VACCINE INSIGHTS ON COVID-19.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO ESTABLISH A SYSTEM FOR CONDUCTING POST-LICENSURE VACCINE SAFETY SURVEILLANCE AND DATA ANALYSIS. THIS NEW SYSTEM ENSURES POLYVAC'S COMPLIANCE WITH LOCAL AND GLOBAL REGULATORY REQUIREMENTS. PATH ALSO SUPPORTED CHINESE VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE HELPED LAUNCH A PHASE 3 CLINICAL STUDY IN KENYA OF A YELLOW FEVER VACCINE FROM BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS. DATA FROM THE STUDY WILL SUPPORT AN APPLICATION FOR WHO PREQUALIFICATION (PQ), A KEY STEP FOR GLOBAL AVAILABILITY. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL OTHER MANUFACTURERS PREPARING FOR WHO PQ SUBMISSION OR INSPECTION; THUS IN 2021, SINOVA BIOTECH LTD'S COVID-19 VACCINE, CORONAVAC, RECEIVED EMERGENCY USE LISTING, AND XIAMEN INNOVAX BIOTECH'S HPV VACCINE, CECOLIN, RECEIVED WHO PQ.

PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. BASED ON THE REAL-WORLD PERFORMANCE OF A NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2), THE WHO STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION (SAGE) ENDORSED WIDER USE OF NOPV2 UNDER THE EMERGENCY USE LISTING. PATH ALSO LAUNCHED A PHASE 3 STUDY OF NOPV2 AND A PHASE 1 STUDY OF NOPV1.

THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH LAUNCHED A NEW

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

STUDY ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. WE ALSO WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING, WITH AN APPLICATION TO GAVI, THE VACCINE ALLIANCE (GAVI) EXPECTED IN 2022.

ALSO IN 2021, WE CONTINUED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE WHO CELEBRATION AND LAUNCH OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP.

PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN 2021, THE VACCINE RECEIVED A RECOMMENDATION FROM WHO FOR BROAD USE TO CURB PLASMODIUM FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO RESEARCHED USE OF THE VACCINE TO AVERT HIGHLY SEASONAL MALARIA ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION. WE CONTINUED WORK TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO PREVENT MALARIA, AND WE CONTINUED WORK ON A FIVE-YEAR CONTRACT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE APPROACHES.

THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2021 WAS HIGHLIGHTING CLIMATE CHANGE AND GENDER INEQUITY AS MAJOR DRIVERS OF CHILD HEALTH OUTCOMES.

TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE WITH THE START OF A PHASE 3 EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO BEGAN A PHASE 2 STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL.

PATH CONTINUED TO SUPPORT CLINICAL TRIALS AND RESEARCH ON VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

EITHER PATHOGEN. WE COMPLETED FURTHER ANALYSIS OF RESULTS FROM A PHASE 2B EFFICACY STUDY OF AN ORAL ETEC VACCINE CANDIDATE (ETVAX) IN FINNISH TRAVELERS TO BENIN, WHICH SHOWED ETVAX VACCINATION REDUCED THE NEED FOR ANTIBIOTICS. IN ADDITION, WE COMPLETED IN-DEPTH EXPLORATORY IMMUNOLOGY ANALYSES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE USING SAMPLES FROM A RECENT PHASE 1 STUDY SUGGESTING EFFECTIVE IMMUNIZATION MAY BE POSSIBLE WITH A SINGLE DOSE.

PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRIZE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS.

AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES: IN MALAWI AND NEPAL, WE CONTINUED TO SUPPORT EACH GOVERNMENT IN PLANNING FOR TCV INTRODUCTION; IN PAKISTAN, WE SUPPORTED THE GOVERNMENT IN PLANNING FOR THE CONCLUSION OF THE NATIONAL ROLLOUT; IN LIBERIA AND ZIMBABWE, WE WRAPPED UP OUR SUPPORT AFTER SUCCESSFUL TCV INTRODUCTION CAMPAIGNS; AND IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES.

TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. THIS INCLUDED SYNTHESIZING NEWLY AVAILABLE, CRITICAL CLINICAL TRIAL DATA TO PREPARE FOR AND PRESENT EVIDENCE TO WHO'S SAGE. A SINGLE-DOSE SCHEDULE WOULD HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE 3 STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES, AND CONTINUED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:  
PATH PUBLISHED SEVERAL ARTICLES ON THE ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG INFANTS IN LMICS, AND ON THE IMPORTANCE OF MATERNAL IMMUNIZATION AND THE STRENGTHENING OF RSV ASSAYS. ADDITIONALLY, PATH UPDATED OUR RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT, WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE, AND OUR TRIAL TRACKER, WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS.

DRUG DEVELOPMENT  
THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS,

OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG

DEVELOPMENT AND USE - FROM EARLY RESEARCH TO INTRODUCTION.

IN 2021, WE CONTINUED DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM,

A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE

TREATMENT IS AVAILABLE. WE DEMONSTRATED THAT OUR LEAD COMPOUND IS

EFFECTIVE IN DAIRY CALVES, A KEY MODEL THAT MIRRORS HUMAN CLINICAL

SYMPTOMS.

WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE COMMERCIALY

LAUNCHED THE MICRONUTRIENT AND EED ASSESSMENT TOOL (MEEDAT), A NEW TOOL

FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) - AN INTESTINAL

DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING

OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. MEEDAT WAS USED IN

STUDIES OF CHILDREN IN ZAMBIA AND TANZANIA, WITH ADDITIONAL STUDIES

PLANNED IN OTHER LOW-RESOURCE SETTINGS.

PATH ALSO EXPLORED NEW USES AND PARTNERSHIPS FOR IOWH032, A DRUG

CANDIDATE WE PREVIOUSLY DEVELOPED FOR TREATMENT OF CHOLERA, WHICH ALSO

HAS POTENTIAL FOR TREATING OTHER DISEASES.

FORM 990, PART III, LINE 4C, PROGRAM SERVICE ACCOMPLISHMENTS:

DRC

IN 2021, PATH'S ENGAGEMENT IN THE DRC FOCUSED ON HIV/AIDS, VACCINATION

(COVID-19 AND POLIO), AND HEALTH SYSTEM STRENGTHENING. FOR EXAMPLE, THE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

USAID INTEGRATED HIV/AIDS PROJECT, WHICH PATH LEADS IN HAUT-KATANGA PROVINCE (IHAP-HK), ACHIEVED THE INTERNATIONAL GOLD STANDARD RATE OF 95% UNDETECTABLE VIRAL LOAD AMONG A COHORT OF 45,000. PATH ALSO SUPPORTED THE COVID-19 RESPONSE, INCLUDING HOSTING THE PRESIDENTIAL COVID-19 TASK FORCE IN OUR KINSHASA OFFICE, CONDUCTING THE FIRST DRC NATIONWIDE OXYGEN AVAILABILITY ASSESSMENT, AND MONITORING COVID-19 VACCINATION (THE LATTER VIA THE USAID M-RITE PROJECT). PATH SUPPORTED THE DRC PRESIDENT'S OFFICE FOR THE SECOND PRESIDENTIAL IMMUNIZATION AND POLIO ERADICATION FORUM.

TO ACCELERATE TWO HIGH-PRIORITY INITIATIVES - THE DIGITAL TRANSFORMATION OF THE COUNTRY'S HEALTH SECTOR AND UNIVERSAL HEALTH COVERAGE - THE MOH, WITH SUPPORT FROM THE DIGITAL SQUARE TEAM WITHIN PATH, LAUNCHED AN INVESTMENT ROAD MAP WITH MORE THAN 60 INSTITUTIONS PARTICIPATING IN PRIORITIZING CATALYTIC INVESTMENTS.

ETHIOPIA WITH FUNDING FROM GAVI THROUGH THE TARGETED COUNTRY ASSISTANCE (TCA) PROJECT, PATH SUPPORTED THE AFAR REGION TO PILOT AND IMPLEMENT CATCH-UP IMMUNIZATION IN TWO CONFLICT-AFFECTED AREAS. PATH ALSO SUPPORTED THE MOH TO IMPLEMENT A VACCINATION STRATEGY DESIGNED SPECIFICALLY FOR COVID-19 VACCINE AND HPV VACCINE, CONDUCTING AN INTEGRATED VACCINATION CAMPAIGN NATIONWIDE FOR TWO COHORTS OF ADOLESCENT GIRLS AND YOUNG WOMEN. IN CLOSE COLLABORATION WITH THE MOH, PATH DESIGNED AND WAS AWARDED A PROJECT FROM BIG WIN PHILANTHROPY TO REVAMP AND RESTORE MATERNAL AND CHILD HEALTH PROGRAMS IN CONFLICT-AFFECTED AREAS, WITH A FOCUS ON EARLY CHILDHOOD DEVELOPMENT AND CAREGIVER HEALTH.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

KENYA

PATH'S NONCOMMUNICABLE DISEASES (NCD) TEAM PARTNERED WITH THE KENYA

GOVERNMENT TO EVALUATE THE NATIONAL NCD STRATEGY 2015-2020 TO INFORM

THE DESIGN AND DEVELOPMENT OF THE NCD STRATEGY 2021-2026. FOLLOWING

LAUNCH OF THE STRATEGY IN JULY 2021, PATH SUPPORTED DISSEMINATION TO

OUR FOCAL COUNTIES.

PATH IS PRIME ON THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, WITH A

FIVE-YEAR (2021-2026) BUDGET OF MORE THAN \$44 MILLION. THROUGH THIS

PROJECT, PATH LEADS A CONSORTIUM THAT PROVIDES HIV SERVICES TO YOUNG

PEOPLE IN HOMA BAY, KISII, AND MIGORI COUNTIES. THROUGH THE DREAMS

INITIATIVE, WE CONTINUED TO SUPPORT HIV PREVENTION FOR ADOLESCENT GIRLS

AND YOUNG WOMEN. WORKING AS A SUBPARTNER, PATH ALSO SUPPORTED BORESHA

JAMII, A PEPFAR-FUNDED USAID PROJECT TO INCREASE ACCESS TO AND DEMAND

FOR HIGH-QUALITY TB/HIV PREVENTION, CARE, AND TREATMENT.

RTS,S, THE WORLD'S FIRST MALARIA VACCINE, WAS DEVELOPED BY GSK OVER

MORE THAN 30 YEARS AND IN PARTNERSHIP WITH PATH SINCE 2001. IN OCTOBER

2021, WHO RECOMMENDED EXPANDING USE OF THE VACCINE ACROSS THE AFRICAN

CONTINENT. WITH PATH SUPPORT, KENYA, ONE OF THE FIRST COUNTRIES TO GAIN

REGULATORY APPROVAL FOR RTS,S, EMBARKED ON A PHASED INTRODUCTION AND

EVALUATION TO LEARN HOW BEST TO IMPLEMENT THE VACCINE WITHIN THE

CONTEXT OF ROUTINE IMMUNIZATION.

THE PATH KENYA LIVING LABS TEAM IN 2021 FINALIZED THE DESIGN AND PILOT

TESTING OF A PROTOTYPE DIGITAL TOOL TO SUPPORT SCHEDULING FOR BOTH

IMMUNIZATION AND PHC SERVICES. THE TOOL COMPLEMENTS AN IMMUNIZATION

DASHBOARD DEVELOPED BY THE LIVING LABS TEAM TO TRACK PERFORMANCE ON KEY

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

INDICATORS ACROSS KENYA'S COUNTIES, SUBCOUNTIES, AND FACILITIES.

KENYA IS ONE OF SEVERAL COUNTRIES RECEIVING SUPPORT THROUGH THE COVID-19 RESPIRATORY CARE RESPONSE COORDINATION PROJECT, A CONSORTIUM FUNDED BY THE BILL & MELINDA GATES FOUNDATION. IN 2021, THE CONSORTIUM, LED BY PATH, PROCURED AND INSTALLED RESPIRATORY CARE EQUIPMENT AT 23 HIGH-VOLUME FACILITIES AND ENSURED THE REPAIR/INSTALLATION OF FIVE OXYGEN GENERATION PLANTS AT TERTIARY/REFERRAL HEALTH FACILITIES. ADDITIONALLY, PATH SUPPORTED KENYAN COUNTIES IN CONDUCTING CAPACITY-BUILDING AND SUPPORTIVE SUPERVISION UNDER THE M-RITE PROJECT, WHICH FOCUSES ON IMMUNIZATION.

SENEGAL

PATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE 3RD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM, A KEY TOOL IN IDENTIFYING, MANAGING, AND MITIGATING INFECTIOUS DISEASE OUTBREAKS. RELATED, PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE (AMR).

PATH SUPPORTED THE GOVERNMENT IN VARIOUS ASPECTS OF ITS COVID-19 RESPONSE, INCLUDING PROCUREMENT OF EQUIPMENT AND REAGENTS FOR DIAGNOSTIC TESTS AS WELL AS INTENSIVE CARE EQUIPMENT FOR TREATMENT OF SEVERE CASES. AT THE COMMUNITY LEVEL, PATH WORKED TO STIMULATE DEMAND FOR COVID-19 VACCINATION.

IN 2021, THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

(TIMCI) PROJECT LAUNCHED IN SENEGAL, AND THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN WITH IMPLEMENTATION AT FOUR INTERVENTION SITES. TIMCI (WITH PATH AS LEAD PARTNER) SUPPORTED THE MOH TO REVISE THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS.

AS PATH'S WESTERN AFRICA HUB, PATH SENEGAL SUPPORTED THE MOH OF GUINEA, A NEIGHBORING COUNTRY, IN INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS, INCLUDING EBOLA, INTO ITS NATIONAL SURVEILLANCE EARLY WARNING SYSTEM. PATH ALSO PROVIDED TECHNICAL ASSISTANCE TO THE GOVERNMENT OF MALI IN THE DIGITALIZATION OF COVID-19 VACCINATION DATA.

TANZANIA  
IN 2021, THE DATA USE PARTNERSHIP, A COLLABORATION BETWEEN PATH AND THE GOVERNMENT OF TANZANIA, LAUNCHED THE AFYA SUPPORTIVE SUPERVISION PLAN TO IMPLEMENT A DIGITAL SYSTEM FOR DATA COLLECTION IN HEALTH FACILITIES. THE PLAN SUPPLIED 900 TABLETS TO NATIONAL- AND REGIONAL-LEVEL USERS, WITH PATH LEVERAGING OUR EXPERTISE TO SUPPORT TRAININGS ON THE EQUIPMENT AND SOFTWARE.

ALSO IN TANZANIA, THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT OPERATIONALIZED A NATIONAL AMR SURVEILLANCE FRAMEWORK. HEALTH WORKERS IN THE COUNTRY CAN NOW SUBMIT HIGH-QUALITY AMR DATA PRODUCED THROUGH THIS FRAMEWORK TO THE NATIONAL DATABASE AND THE GLOBAL AMR SURVEILLANCE SYSTEM.

IN COLLABORATION WITH THE MOH, PATH LAUNCHED THE TIMCI PROJECT IN THREE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

DISTRICTS. WORK IN 2021 INCLUDED DEVELOPING, DEPLOYING, AND SUPPORTING IMPLEMENTATION OF AN ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHM.

PATH'S DIGITAL SQUARE INITIATIVE SUPPORTED THE MOH IN IMPLEMENTING A STANDARDS-BASED NATIONAL HEALTH INFORMATION EXCHANGE PLATFORM THAT BY CLOSE OF 2021 ALLOWED FOR EXCHANGE OF DATA BETWEEN 13 DISPARATE HEALTH INFORMATION SYSTEMS. THROUGH GAVI/TCA, PATH SUPPORTED THE MOH TO TRANSITION FROM A TRADITIONAL, PAPER-BASED SYSTEM FOR IMMUNIZATION TRACKING TO FULL ELECTRONIC DATA COLLECTION AND MANAGEMENT IN MORE THAN 600 PHC FACILITIES. SEPARATELY, PATH SUPPORTED THE MOH TO DEVELOP A RESPIRATORY CARE EQUIPMENT BASELINE ASSESSMENT TOOL, MEDICAL OXYGEN TRAINING MANUAL, AND SCALE-UP PLAN.

IN LATE 2021, THE HEALTHY HEART AFRICA PROJECT BEGAN IN TANZANIA WITH THE SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN THE MOH AND ASTRAZENECA, AFTER WHICH PATH CONDUCTED A STAKEHOLDER WORKSHOP TO INTRODUCE THE PROJECT AND ENSURE GOVERNMENT COMMITMENT AND ACCOUNTABILITY.

UGANDA  
IN 2021, PATH'S ADVOCACY AND PUBLIC POLICY TEAM IN UGANDA INFLUENCED THE INTRODUCTION OF A SUPPLEMENTARY BUDGET FOR COVID-19 VACCINATION AND ENSURED BUDGET INCREASES FROM PREVIOUS YEARS FOR ROUTINE IMMUNIZATION AND PHC WERE MAINTAINED DESPITE BUDGET SHORTFALLS AT THE NATIONAL LEVEL.

PATH SUCCESSFULLY ADVOCATED FOR THE PASSAGE OF A NATIONAL HEALTH INSURANCE SCHEME AND HELPED DEVELOP A UNIVERSAL HEALTH COVERAGE ROAD

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

MAP AND COMMUNITY HEALTH EXTENSION WORKERS STRATEGY IN PILOT DISTRICTS.  
 OUR TEAM ADVOCATED FOR INTEGRATION OF THE ADDIS DECLARATION ON  
 IMMUNIZATION COMMITMENTS INTO EXPANDED PROGRAM ON IMMUNIZATION WORK  
 PLANS BY CREATING AND DISSEMINATING A SCORECARD TOOL TO SERVE AS AN  
 ACCOUNTABILITY FRAMEWORK. PATH IN UGANDA ALSO ADVOCATED FOR  
 PRIORITIZATION OF ROUTINE IMMUNIZATION TO PREVENT BACKSLIDING DURING  
 COVID-19, WITH A FOCUS ON CATCH-UP CAMPAIGNS SUCH AS A NATIONAL POLIO  
 IMMUNIZATION CAMPAIGN. PATH ALSO SUPPORTED THE MOH TO DISSEMINATE  
 GUIDELINES ON THE CONTINUITY OF ESSENTIAL HEALTH SERVICES DURING  
 COVID-19 AT THE SUBNATIONAL LEVEL, REACHING MORE THAN 400 CHAMPIONS AND  
 HEALTH CARE WORKERS THROUGH TECHNICAL WORKSHOPS AND TRAININGS.

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:  
 THROUGH THE IDDS PROJECT, PATH SUPPORTED THE MINISTRY OF AGRICULTURE,  
 ANIMAL INDUSTRIES AND FISHERIES (MAAIF) TO INSTRUCT THE FIRST-EVER  
 ISO/IEC 17025:2017 (THE QUALITY STANDARD FOR OPERATION OF LABORATORIES)  
 TRAINER OF TRAINERS COHORT IN THE COUNTRY AS PART OF A GLOBAL HEALTH  
 SECURITY EFFORT TO IMPROVE DETECTION OF PRIORITY ZOO NOTIC DISEASES.  
 WORKING WITH RELEVANT NATIONAL STAKEHOLDERS, PATH DRAFTED AND  
 OPERATIONALIZED A UGANDA STRATEGY FOR COORDINATED AND INTEGRATED  
 SURVEILLANCE OF THESE DISEASES. PATH SUPPORTED THE NATIONAL ANIMAL  
 DISEASES DIAGNOSTICS AND EPIDEMIOLOGY CENTER AND THE ANIMAL HEALTH  
 NATIONAL REFERENCE LABORATORY WITHIN MAAIF TO IMPROVE DATA ENTRY,  
 QUALITY, ANALYSIS, AND REPORTING. ALSO THROUGH IDDS, PATH REVITALIZED  
 FACILITY- AND COMMUNITY-BASED SURVEILLANCE FOR COVID-19 IN EASTERN  
 UGANDA.

PATH ALSO SUPPORTED THE DEVELOPMENT OF STANDARD OPERATING PROCEDURES

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

AND WASTE MANAGEMENT GUIDELINES FOR COVID-19 VACCINATION ROLLOUT AND PROVIDED REGULATORY SUPPORT TO THE MOH TO EXPEDITE COVID-19 VACCINE AUTHORIZATION AND SHIPMENT INTO THE COUNTRY.

FURTHERMORE IN UGANDA, PATH SUPPORTED COUNTRYWIDE COLD CHAIN EQUIPMENT REPAIR AND MAINTENANCE WHEREBY MORE THAN 100 NONFUNCTIONAL COLD CHAIN DEVICES, SUCH AS VACCINE REFRIGERATORS, WERE REPAIRED. WE EXPANDED THE SCOPE OF THE COLD CHAIN INFORMATION SYSTEM TO INCLUDE COUNTRY-SPECIFIC REQUIREMENTS AND INVENTORY DATA FOR IMPROVED COLD CHAIN EQUIPMENT MANAGEMENT.

THROUGH THE UNITAID HIV STAR III INITIATIVE, UGANDA HAS ACHIEVED SIGNIFICANT SCALE-UP IN HIV SELF-TESTING (HIVST) SERVICES. THE COUNTRY IS SET TO DISTRIBUTE 3.5 MILLION HIVST KITS ANNUALLY, MAKING IT THE LARGEST HIVST MARKET GLOBALLY. PATH DEVELOPED THE POST-MARKET SURVEILLANCE NATIONAL PLAN AND STANDARD OPERATING PROCEDURES FOR HIVST.

PATH ALSO INTRODUCED TWO WHO-PREQUALIFIED BLOOD-BASED KITS INTO THE COUNTRY TO EXPAND CHOICE AND ACCESS. PATH INTEGRATED THE KITS INTO THE SUPPLY CHAIN AND OTHER SYSTEMS, LEADING TO THE GOVERNMENT'S REVIEW AND ADOPTION OF HIVST TRAINING MATERIALS FOR HEALTH CARE WORKERS AND DEVELOPMENT OF TRAINING MATERIALS FOR PEER HIVST DISTRIBUTORS.

ZAMBIA  
IN PARTNERSHIP WITH THE ZAMBIA GOVERNMENT, PATH SUPPORTED HIGH-QUALITY, CUTTING-EDGE RESEARCH ON PRESSING HEALTH ISSUES, FROM COVID-19 TO MALARIA TO TB. FURTHERMORE, PATH IMPLEMENTED NEW DIGITAL HEALTH TOOLS AND APPROACHES ACROSS THE COUNTRY, FROM OUR PRIVATE-SECTOR PARTNERSHIP "VISUALIZE NO MALARIA" TO THE BETTER IMMUNIZATION DATA INITIATIVE.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

IN 2021, WE CONTINUED TO SUPPORT THE GOVERNMENT RESPONSE TO THE COVID-19 PANDEMIC. ONE NEW OPPORTUNITY WAS A BAYER-FUNDED PROJECT TO SUPPORT THE MOH ON KEY ASPECTS OF COVID-19 VACCINE ROLLOUT AND DISEASE SURVEILLANCE. ADDITIONALLY, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO THE MOH ON COVID-19 PROTECTIVE MEASURES.

IN 2021, THE LIVING LABS PROJECT IN ZAMBIA ENGAGED FRONTLINE IMMUNIZATION HEALTH WORKERS TO IMPROVE VACCINE DELIVERY AND COVERAGE. THROUGH THIS PROJECT, THE WORKERS HELPED ADVISE ON LABELING FOR COVID-19 VACCINES AND HOW TO BEST ACCELERATE VACCINE DISTRIBUTION IN THEIR COMMUNITIES. THEIR FEEDBACK WILL IMPROVE VACCINATION COVERAGE FOR COVID-19 AND BEYOND.

OUR WORK IN MALARIA IN ZAMBIA INCLUDED GROUNDBREAKING RESEARCH BY OUR LABORATORY TEAM BASED AT THE NATIONAL MALARIA ELIMINATION CENTER, EVALUATION OF NEW VECTOR-CONTROL TOOLS (SUCH AS THE ATTRACTIVE TARGETED SUGAR BAIT), AND TRAINING OF HEALTH WORKERS ON NEW MALARIA CONTROL GUIDELINES AND PROCEDURES, INCLUDING AT THE COMMUNITY LEVEL.

PATH ALSO INCREASED THE NUMBER OF PEOPLE TESTED AND TREATED FOR TB IN ZAMBIA, EXPANDED TB CARE, AND CREATED STRATEGIES TO ADDRESS PEDIATRIC AND DRUG-RESISTANT TB, INCLUDING TRAINING HEALTH WORKERS ON NEW GUIDELINES AND INVESTING IN EFFECTIVE DIAGNOSTICS AT LABORATORIES ACROSS THE COUNTRY.

FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES:

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

ADVOCACY AND PUBLIC POLICY

PATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN AFRICA (DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS.

PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2021, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY U.S. GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE TO COVID-19.

ASIA, MIDDLE EAST, AND EUROPE REGION

PATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR DEEP EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION. HIGHLIGHTS INCLUDE:

IN 2021, PATH CONTINUED TO COLLABORATE CLOSELY WITH STAKEHOLDERS TO DELIVER HIGH-QUALITY HEALTH SERVICES WHILE FORGING NEW PARTNERSHIPS IN COUNTRIES SUCH AS BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.

PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT PANDEMIC RESPONSE. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE LONG-NEGLECTED DISEASES SUCH AS LEISHMANIASIS AND ENSURE THAT THOSE INFECTED RECEIVE CARE.

THANKS TO OUR CONTINUOUS WORK IN DEVELOPING INNOVATIVE DIGITAL HEALTH TOOLS, PATH WAS ABLE TO MAINTAIN ESSENTIAL HEALTH SERVICES FOR KEY POPULATIONS IN MYANMAR, DIGITIZE THE LACTATION MANAGEMENT SYSTEM IN INDIA, AND SUPPORT MEDICATION ADHERENCE FOR TB PATIENTS IN UKRAINE.

THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING HEALTH SYSTEM CAPACITY AND RESILIENCE WITH COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO HARD-TO-REACH COMMUNITIES. IN VIETNAM, FOR EXAMPLE, WE IMPLEMENTED A HIGHLY SUCCESSFUL PROGRAM FOR HIV SELF-TESTING.

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

PATH IN THE AMEE REGION ALSO CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND MENINGITIS; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL.

EXPENSES \$ 41,899,328. INCLUDING GRANTS OF \$ 5,057,232. REVENUE \$ 0.

FORM 990, PART V, LINE 4B, LIST OF FOREIGN COUNTRIES:

BELGIUM, CHINA, ETHIOPIA, GHANA, INDIA, KENYA, MOZAMBIQUE, PERU, SENEGAL, SWITZERLAND, TANZANIA, UGANDA, UNITED KINGDOM, VIETNAM, ZAMBIA, CONGO, DEM REP, MALAWI, BURMA, SOUTH AFRICA, UKRAINE

FORM 990, PART VI, SECTION B, LINE 11B:

THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM.

FORM 990, PART VI, SECTION B, LINE 12C:

PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN

IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED

CONFLICT OF INTEREST.

PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL

AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS

ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS

OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN

ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE

OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY

PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE

IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE

GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO

PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON

WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE

NEXT REGULARLY SCHEDULED BOARD MEETING.

FORM 990, PART VI, SECTION B, LINE 15:

THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND

BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE

PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR

EXECUTIVE POSITIONS.

THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND

APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR.

PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK

EXECUTIVE COMPENSATION (PRESIDENT/CEO AND DIVISION CHIEFS). THE MOST RECENT

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2021. AT THE REQUEST OF THE BOARD, PATH ENGAGED FUTURE SENSE (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND DIVISION CHIEFS.

FUTURE SENSE USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE FUTURE SENSE REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE DIVISION CHIEFS.

ADDITIONALLY, FUTURE SENSE REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:  
AL, AR, CA, CT, FL, IL, KS, KY, MA, MD, MI, MN, MS, NC, NH, NJ, NM, NY, OK, OR, PA, RI, SC, TN, UT  
VA, WI, WV

FORM 990, PART VI, SECTION C, LINE 19:  
PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE.

**SCHEDULE R  
(Form 990)**

Department of the Treasury  
Internal Revenue Service

**Related Organizations and Unrelated Partnerships**

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.  
▶ Attach to Form 990.

▶ Go to [www.irs.gov/Form990](http://www.irs.gov/Form990) for instructions and the latest information.

OMB No. 1545-0047

**2021**  
Open to Public Inspection

Name of the organization PATH	Employer identification number 91-1157127
----------------------------------	--

**Part I Identification of Disregarded Entities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

**Part II Identification of Related Tax-Exempt Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?	
						Yes	No
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND, 207 ROUTE DE FERNEY 1218 LE GRAND-SACONNEX, GENEVA, SWITZERLAND	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	SWITZERLAND	501(C)(3)		PATH	X	
PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA, ACS PLAZA 4TH FL., LENANA RD PO BOX 76634-00508, NAIROBI, KENYA	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	KENYA	501(C)(3)		PATH	X	



**Part V Transactions With Related Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

**Note:** Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

	Yes	No
<b>1</b> During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?		
<b>a</b> Receipt of <b>(i)</b> interest, <b>(ii)</b> annuities, <b>(iii)</b> royalties, or <b>(iv)</b> rent from a controlled entity .....		X
<b>b</b> Gift, grant, or capital contribution to related organization(s) .....	X	
<b>c</b> Gift, grant, or capital contribution from related organization(s) .....	X	
<b>d</b> Loans or loan guarantees to or for related organization(s) .....		X
<b>e</b> Loans or loan guarantees by related organization(s) .....		X
<b>f</b> Dividends from related organization(s) .....		X
<b>g</b> Sale of assets to related organization(s) .....		X
<b>h</b> Purchase of assets from related organization(s) .....		X
<b>i</b> Exchange of assets with related organization(s) .....		X
<b>j</b> Lease of facilities, equipment, or other assets to related organization(s) .....		X
<b>k</b> Lease of facilities, equipment, or other assets from related organization(s) .....		X
<b>l</b> Performance of services or membership or fundraising solicitations for related organization(s) .....		X
<b>m</b> Performance of services or membership or fundraising solicitations by related organization(s) .....		X
<b>n</b> Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) .....		X
<b>o</b> Sharing of paid employees with related organization(s) .....		X
<b>p</b> Reimbursement paid to related organization(s) for expenses .....		X
<b>q</b> Reimbursement paid by related organization(s) for expenses .....		X
<b>r</b> Other transfer of cash or property to related organization(s) .....		X
<b>s</b> Other transfer of cash or property from related organization(s) .....		X

**2** If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA	C	2,279,943	FMV
(2) FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND	B	5,789,794	FMV
(3)			
(4)			
(5)			
(6)			



